PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34952420-17	2022	We also found that the expression of p-mTOR, P62, and Beclin1 was significantly increased and that LC3II/LC3I declined after LPS stimulation, but the effect was inhibited by treatment with GYY4137, indicating that GYY4137 could inhibit the activation of autophagy in sepsis-induced ALI by blocking mTOR signaling.	GYY 4137	189-196	mechanistic target of rapamycin kinase	Mus musculus	39-43
34952420-15	2022	In this study, we found that GYY4137 could alleviate septicemia-induced ferroptosis in ALI by increasing the expression of GPx4 and SLC7A11 in lung tissue after CLP.	GYY 4137	29-36	glutathione peroxidase 4	Mus musculus	123-127
34952420-17	2022	We also found that the expression of p-mTOR, P62, and Beclin1 was significantly increased and that LC3II/LC3I declined after LPS stimulation, but the effect was inhibited by treatment with GYY4137, indicating that GYY4137 could inhibit the activation of autophagy in sepsis-induced ALI by blocking mTOR signaling.	GYY 4137	189-196	beclin 1, autophagy related	Mus musculus	54-61
34952420-15	2022	In this study, we found that GYY4137 could alleviate septicemia-induced ferroptosis in ALI by increasing the expression of GPx4 and SLC7A11 in lung tissue after CLP.	GYY 4137	29-36	solute carrier family 7 (cationic amino acid transporter, y+ system), member 11	Mus musculus	132-139
34952420-17	2022	We also found that the expression of p-mTOR, P62, and Beclin1 was significantly increased and that LC3II/LC3I declined after LPS stimulation, but the effect was inhibited by treatment with GYY4137, indicating that GYY4137 could inhibit the activation of autophagy in sepsis-induced ALI by blocking mTOR signaling.	GYY 4137	189-196	mechanistic target of rapamycin kinase	Mus musculus	298-302
34952420-17	2022	We also found that the expression of p-mTOR, P62, and Beclin1 was significantly increased and that LC3II/LC3I declined after LPS stimulation, but the effect was inhibited by treatment with GYY4137, indicating that GYY4137 could inhibit the activation of autophagy in sepsis-induced ALI by blocking mTOR signaling.	GYY 4137	214-221	mechanistic target of rapamycin kinase	Mus musculus	39-43
34952420-17	2022	We also found that the expression of p-mTOR, P62, and Beclin1 was significantly increased and that LC3II/LC3I declined after LPS stimulation, but the effect was inhibited by treatment with GYY4137, indicating that GYY4137 could inhibit the activation of autophagy in sepsis-induced ALI by blocking mTOR signaling.	GYY 4137	214-221	beclin 1, autophagy related	Mus musculus	54-61
34952420-17	2022	We also found that the expression of p-mTOR, P62, and Beclin1 was significantly increased and that LC3II/LC3I declined after LPS stimulation, but the effect was inhibited by treatment with GYY4137, indicating that GYY4137 could inhibit the activation of autophagy in sepsis-induced ALI by blocking mTOR signaling.	GYY 4137	214-221	mechanistic target of rapamycin kinase	Mus musculus	298-302
34792020-6	2021	Mechanistically, GYY4137 blocked HIV reactivation by inducing the Keap1-Nrf2 pathway, inhibiting NF-kB, and recruiting the epigenetic silencer, YY1, to the HIV promoter.	GYY 4137	17-24	kelch like ECH associated protein 1	Homo sapiens	66-71
34597656-6	2021	The RNA sequencing analysis demonstrated that GYY4137 modulated the mRNA expression of the genes involved in the G2/M and the spindle assembly checkpoints; increased mRNA levels of Cdkn1a, Gadd45a, and Sfn and decreased mRNA levels of Cdc20, Pttg1, and Ccnb1 were observed.	GYY 4137	46-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	181-187
34597656-6	2021	The RNA sequencing analysis demonstrated that GYY4137 modulated the mRNA expression of the genes involved in the G2/M and the spindle assembly checkpoints; increased mRNA levels of Cdkn1a, Gadd45a, and Sfn and decreased mRNA levels of Cdc20, Pttg1, and Ccnb1 were observed.	GYY 4137	46-53	growth arrest and DNA damage inducible alpha	Homo sapiens	189-196
34597656-6	2021	The RNA sequencing analysis demonstrated that GYY4137 modulated the mRNA expression of the genes involved in the G2/M and the spindle assembly checkpoints; increased mRNA levels of Cdkn1a, Gadd45a, and Sfn and decreased mRNA levels of Cdc20, Pttg1, and Ccnb1 were observed.	GYY 4137	46-53	RNA exonuclease 2	Homo sapiens	202-205
34597656-6	2021	The RNA sequencing analysis demonstrated that GYY4137 modulated the mRNA expression of the genes involved in the G2/M and the spindle assembly checkpoints; increased mRNA levels of Cdkn1a, Gadd45a, and Sfn and decreased mRNA levels of Cdc20, Pttg1, and Ccnb1 were observed.	GYY 4137	46-53	cell division cycle 20	Homo sapiens	235-240
34597656-6	2021	The RNA sequencing analysis demonstrated that GYY4137 modulated the mRNA expression of the genes involved in the G2/M and the spindle assembly checkpoints; increased mRNA levels of Cdkn1a, Gadd45a, and Sfn and decreased mRNA levels of Cdc20, Pttg1, and Ccnb1 were observed.	GYY 4137	46-53	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	242-247
34597656-6	2021	The RNA sequencing analysis demonstrated that GYY4137 modulated the mRNA expression of the genes involved in the G2/M and the spindle assembly checkpoints; increased mRNA levels of Cdkn1a, Gadd45a, and Sfn and decreased mRNA levels of Cdc20, Pttg1, and Ccnb1 were observed.	GYY 4137	46-53	cyclin B1	Homo sapiens	253-258
34792020-6	2021	Mechanistically, GYY4137 blocked HIV reactivation by inducing the Keap1-Nrf2 pathway, inhibiting NF-kB, and recruiting the epigenetic silencer, YY1, to the HIV promoter.	GYY 4137	17-24	NFE2 like bZIP transcription factor 2	Homo sapiens	72-76
34597656-8	2021	Besides, studies exploring the MEK inhibitor indicated that MEK activation is involved in the GYY4137-mediated increase in the Sfn expression.	GYY 4137	94-101	mitogen-activated protein kinase kinase 7	Homo sapiens	60-63
34597656-8	2021	Besides, studies exploring the MEK inhibitor indicated that MEK activation is involved in the GYY4137-mediated increase in the Sfn expression.	GYY 4137	94-101	RNA exonuclease 2	Homo sapiens	127-130
34792020-6	2021	Mechanistically, GYY4137 blocked HIV reactivation by inducing the Keap1-Nrf2 pathway, inhibiting NF-kB, and recruiting the epigenetic silencer, YY1, to the HIV promoter.	GYY 4137	17-24	YY1 transcription factor	Homo sapiens	144-147
34792020-7	2021	In latently infected CD4+ T cells from ART-suppressed human subjects, GYY4137 in combination with ART prevented viral rebound and improved mitochondrial bioenergetics.	GYY 4137	70-77	CD4 molecule	Homo sapiens	21-24
35628328-8	2022	H2S inhalation for 1.5 h, as well as GYY 4137 treatment, increased p38 phosphorylation.	GYY 4137	37-45	mitogen activated protein kinase 14	Rattus norvegicus	67-70
34534609-4	2021	In this study we reported that exogenous H2S donors NaHS and GYY4137 (GYY) enhanced the autophagy activity, as indicated by the increases of autophagy marker LC3-II expression and LC3 dots formation even during lysosome inhibition in dopaminergic cell lines and HEK293 cells.	GYY 4137	61-68	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	158-161
34534609-4	2021	In this study we reported that exogenous H2S donors NaHS and GYY4137 (GYY) enhanced the autophagy activity, as indicated by the increases of autophagy marker LC3-II expression and LC3 dots formation even during lysosome inhibition in dopaminergic cell lines and HEK293 cells.	GYY 4137	61-68	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	180-183
34534609-4	2021	In this study we reported that exogenous H2S donors NaHS and GYY4137 (GYY) enhanced the autophagy activity, as indicated by the increases of autophagy marker LC3-II expression and LC3 dots formation even during lysosome inhibition in dopaminergic cell lines and HEK293 cells.	GYY 4137	70-73	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	158-161
34534609-4	2021	In this study we reported that exogenous H2S donors NaHS and GYY4137 (GYY) enhanced the autophagy activity, as indicated by the increases of autophagy marker LC3-II expression and LC3 dots formation even during lysosome inhibition in dopaminergic cell lines and HEK293 cells.	GYY 4137	70-73	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	180-183
34356307-5	2021	Our results revealed the anxiolytic, antidepressant, and antinociceptive properties of DADS and GYY4137 during neuropathic pain by inhibiting microglial activation and the up-regulation of phosphoinositide 3-kinase/phosphorylated protein kinase B and BAX in the amygdala (AMG) and/or periaqueductal gray matter (PAG).	GYY 4137	96-103	BCL2-associated X protein	Mus musculus	251-254
34311523-0	2021	GYY4137 attenuates functional impairment of corpus cavernosum and reduces fibrosis in rats with STZ-induced diabetes by inhibiting the TGF-beta1/Smad/CTGF pathway.	GYY 4137	0-7	transforming growth factor, beta 1	Rattus norvegicus	135-144
34311523-0	2021	GYY4137 attenuates functional impairment of corpus cavernosum and reduces fibrosis in rats with STZ-induced diabetes by inhibiting the TGF-beta1/Smad/CTGF pathway.	GYY 4137	0-7	cellular communication network factor 2	Rattus norvegicus	150-154
34358552-5	2021	KEY FINDINGS: H2S restored the villus/crypt depth ratio caused by CT. NaHS and GYY 4137 increased the expression of NF-kappaB1 and for the NF-kappaBIA gene, only GYY 4137 increased the expression of this gene.	GYY 4137	79-87	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-126
34679766-7	2021	Treatment with DADS and/or GYY4137 inhibited: oxidative stress in the amygdala; phosphoinositide 3-kinase overexpression in the amygdala, periaqueductal gray matter, and anterior cingulate cortex; protein kinase B activation in the amygdala and infralimbic cortex; up-regulation of inducible nitric oxide synthase in the amygdala, periaqueductal gray matter and infralimbic cortex and apoptotic responses in the amygdala.	GYY 4137	27-34	nitric oxide synthase 2, inducible	Mus musculus	282-313
34680110-16	2021	In conclusion, our data suggest that RXR signaling plays a significant role in ECM turnover, and GYY4137 modulates PPAR/RAR-mediated RXR signaling to ameliorate PAI-1-dependent adverse ECM turnover in DN.	GYY 4137	97-104	peroxisome proliferator activated receptor alpha	Mus musculus	115-119
34680110-16	2021	In conclusion, our data suggest that RXR signaling plays a significant role in ECM turnover, and GYY4137 modulates PPAR/RAR-mediated RXR signaling to ameliorate PAI-1-dependent adverse ECM turnover in DN.	GYY 4137	97-104	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	161-166
34143548-0	2021	GYY4137 protected the integrity of the blood-brain barrier via activation of the Nrf2/ARE pathway in mice with sepsis.	GYY 4137	0-7	nuclear factor, erythroid derived 2, like 2	Mus musculus	81-85
34143548-8	2021	Furthermore, GYY4137 activated the Nrf2/ARE pathway through the sulfhydrylation of Keap1 and inhibited oxidative stress.	GYY 4137	13-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	35-39
34143548-8	2021	Furthermore, GYY4137 activated the Nrf2/ARE pathway through the sulfhydrylation of Keap1 and inhibited oxidative stress.	GYY 4137	13-20	kelch-like ECH-associated protein 1	Mus musculus	83-88
34143548-9	2021	ML385, the specific inhibitor of Nrf2, significantly reversed the protective effects of GYY4137 in sepsis mice.	GYY 4137	88-95	nuclear factor, erythroid derived 2, like 2	Mus musculus	33-37
34143548-10	2021	In conclusion, this study indicated that through the sulfhydrylation of Keap1, GYY4137 activated the Nrf2/ARE pathway and exerted anti-inflammatory, anti-apoptotic and antioxidant effects in septic mice that consequently protected the integrity of the BBB and improved the clinical outcome of sepsis.	GYY 4137	79-86	kelch-like ECH-associated protein 1	Mus musculus	72-77
34143548-10	2021	In conclusion, this study indicated that through the sulfhydrylation of Keap1, GYY4137 activated the Nrf2/ARE pathway and exerted anti-inflammatory, anti-apoptotic and antioxidant effects in septic mice that consequently protected the integrity of the BBB and improved the clinical outcome of sepsis.	GYY 4137	79-86	nuclear factor, erythroid derived 2, like 2	Mus musculus	101-105
34135757-9	2021	GYY4137 treatment ameliorated lung injury and suppressed inflammatory state and oxidative stress in lung tissues of Cse -/- mice.	GYY 4137	0-7	cystathionase (cystathionine gamma-lyase)	Mus musculus	116-119
35464091-5	2022	The IM-induced expressions of Muscle RING finger 1 (MuRF1) and atrogin-1, two muscle-specific E3 ubiquitin ligases, were decreased by administration of GYY4137 or NaHS.	GYY 4137	152-159	tripartite motif-containing 63	Mus musculus	30-50
35464091-8	2022	It was found that administration of either GYY4137 or NaHS significantly attenuated immobilization-induced oxidative stress as indicated by decreased H2O2 levels and 8-hydroxy-2"-deoxyguanosine (8-OHdG) immunoreactivity, as well as increased total antioxidant capacity (T-AOC), nuclear factor erythroid-2-related factor 2 (NRF2) and NRF2 downstream anti-oxidant targets levels in skeletal muscles.	GYY 4137	43-50	nuclear factor, erythroid derived 2, like 2	Mus musculus	323-327
35464091-8	2022	It was found that administration of either GYY4137 or NaHS significantly attenuated immobilization-induced oxidative stress as indicated by decreased H2O2 levels and 8-hydroxy-2"-deoxyguanosine (8-OHdG) immunoreactivity, as well as increased total antioxidant capacity (T-AOC), nuclear factor erythroid-2-related factor 2 (NRF2) and NRF2 downstream anti-oxidant targets levels in skeletal muscles.	GYY 4137	43-50	nuclear factor, erythroid derived 2, like 2	Mus musculus	333-337
35464091-5	2022	The IM-induced expressions of Muscle RING finger 1 (MuRF1) and atrogin-1, two muscle-specific E3 ubiquitin ligases, were decreased by administration of GYY4137 or NaHS.	GYY 4137	152-159	tripartite motif-containing 63	Mus musculus	52-57
35464091-5	2022	The IM-induced expressions of Muscle RING finger 1 (MuRF1) and atrogin-1, two muscle-specific E3 ubiquitin ligases, were decreased by administration of GYY4137 or NaHS.	GYY 4137	152-159	F-box protein 32	Mus musculus	63-72
35464091-7	2022	Moreover, administration of GYY4137 or NaHS alleviated the IM-induced infiltration of CD45 + leukocytes, meanwhile inhibited the expressions of the pro-inflammatory biomarkers in skeletal muscles.	GYY 4137	28-35	protein tyrosine phosphatase, receptor type, C	Mus musculus	86-90
35464091-8	2022	It was found that administration of either GYY4137 or NaHS significantly attenuated immobilization-induced oxidative stress as indicated by decreased H2O2 levels and 8-hydroxy-2"-deoxyguanosine (8-OHdG) immunoreactivity, as well as increased total antioxidant capacity (T-AOC), nuclear factor erythroid-2-related factor 2 (NRF2) and NRF2 downstream anti-oxidant targets levels in skeletal muscles.	GYY 4137	43-50	nuclear factor, erythroid derived 2, like 2	Mus musculus	278-321
33369105-8	2021	Incubation with GYY4137 (100microM) and AP39 (30nM and 300nM) inhibited the increase in IL-6 and TNF-alpha levels, but not IL-1beta at concentrations that they affected tracheal hyperreactivity.	GYY 4137	16-23	interleukin 6	Mus musculus	88-92
33737083-7	2021	Furthermore, supplementation with GYY4137 reduced glucocorticoid secretion; inhibited glucocorticoid receptor alpha activity by sulfhydration; downregulated vitamin D 1alpha-hydroxylase expression; and upregulated 24-hydroxylase, calbindin-D28k, and sodium phosphate cotransporter 2a expression in the kidney; thereby inhibiting calcium and phosphorus loss induced by fracture.	GYY 4137	34-41	solute carrier family 34 member 1	Rattus norvegicus	250-283
33369105-8	2021	Incubation with GYY4137 (100microM) and AP39 (30nM and 300nM) inhibited the increase in IL-6 and TNF-alpha levels, but not IL-1beta at concentrations that they affected tracheal hyperreactivity.	GYY 4137	16-23	tumor necrosis factor	Mus musculus	97-106
33577850-0	2021	GYY4137 alleviates sepsis-induced acute lung injury in mice by inhibiting the PDGFRbeta/Akt/NF-kappaB/NLRP3 pathway.	GYY 4137	0-7	platelet derived growth factor receptor, beta polypeptide	Mus musculus	78-87
33864412-8	2021	In diabetic kidneys, ubiquitinated CBS and nitrotyrosine were increased but restored by GYY4137.	GYY 4137	88-95	cystathionine beta-synthase	Mus musculus	35-38
33910212-0	2021	Protective Effects of GYY4137 on Renal Ischaemia/Reperfusion Injury through Nrf2-Mediated Antioxidant Defence.	GYY 4137	22-29	nuclear factor, erythroid derived 2, like 2	Mus musculus	76-80
33910212-13	2021	GYY4137 significantly elevated the nuclear translocation of nuclear factor-erythroid-2-related factor 2 (Nrf2) and the expression of antioxidant enzymes regulated by Nrf2, including SOD, HO-1, and NQO-1.	GYY 4137	0-7	nuclear factor, erythroid derived 2, like 2	Mus musculus	60-103
33910212-13	2021	GYY4137 significantly elevated the nuclear translocation of nuclear factor-erythroid-2-related factor 2 (Nrf2) and the expression of antioxidant enzymes regulated by Nrf2, including SOD, HO-1, and NQO-1.	GYY 4137	0-7	nuclear factor, erythroid derived 2, like 2	Mus musculus	105-109
33910212-13	2021	GYY4137 significantly elevated the nuclear translocation of nuclear factor-erythroid-2-related factor 2 (Nrf2) and the expression of antioxidant enzymes regulated by Nrf2, including SOD, HO-1, and NQO-1.	GYY 4137	0-7	nuclear factor, erythroid derived 2, like 2	Mus musculus	166-170
33910212-13	2021	GYY4137 significantly elevated the nuclear translocation of nuclear factor-erythroid-2-related factor 2 (Nrf2) and the expression of antioxidant enzymes regulated by Nrf2, including SOD, HO-1, and NQO-1.	GYY 4137	0-7	heme oxygenase 1	Mus musculus	187-191
33910212-13	2021	GYY4137 significantly elevated the nuclear translocation of nuclear factor-erythroid-2-related factor 2 (Nrf2) and the expression of antioxidant enzymes regulated by Nrf2, including SOD, HO-1, and NQO-1.	GYY 4137	0-7	NAD(P)H dehydrogenase, quinone 1	Mus musculus	197-202
33910212-14	2021	CONCLUSIONS: GYY4137 alleviates ischaemia reperfusion-induced renal injury through activating the antioxidant effect mediated by Nrf2 signalling.	GYY 4137	13-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	129-133
33577850-0	2021	GYY4137 alleviates sepsis-induced acute lung injury in mice by inhibiting the PDGFRbeta/Akt/NF-kappaB/NLRP3 pathway.	GYY 4137	0-7	thymoma viral proto-oncogene 1	Mus musculus	88-91
33577850-0	2021	GYY4137 alleviates sepsis-induced acute lung injury in mice by inhibiting the PDGFRbeta/Akt/NF-kappaB/NLRP3 pathway.	GYY 4137	0-7	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	92-101
33577850-0	2021	GYY4137 alleviates sepsis-induced acute lung injury in mice by inhibiting the PDGFRbeta/Akt/NF-kappaB/NLRP3 pathway.	GYY 4137	0-7	NLR family, pyrin domain containing 3	Mus musculus	102-107
33577850-4	2021	This study aimed to investigate whether GYY4137 inhibits the activation of the pyrin domain-containing protein 3 (NLRP3) inflammasome by inhibiting the PDGFRbeta/Akt/NF-kappaB pathway.	GYY 4137	40-47	pyrin domain-containing protein 3	Mus musculus	79-112
33577850-4	2021	This study aimed to investigate whether GYY4137 inhibits the activation of the pyrin domain-containing protein 3 (NLRP3) inflammasome by inhibiting the PDGFRbeta/Akt/NF-kappaB pathway.	GYY 4137	40-47	NLR family, pyrin domain containing 3	Mus musculus	114-119
33577850-4	2021	This study aimed to investigate whether GYY4137 inhibits the activation of the pyrin domain-containing protein 3 (NLRP3) inflammasome by inhibiting the PDGFRbeta/Akt/NF-kappaB pathway.	GYY 4137	40-47	platelet derived growth factor receptor, beta polypeptide	Mus musculus	152-161
33577850-4	2021	This study aimed to investigate whether GYY4137 inhibits the activation of the pyrin domain-containing protein 3 (NLRP3) inflammasome by inhibiting the PDGFRbeta/Akt/NF-kappaB pathway.	GYY 4137	40-47	thymoma viral proto-oncogene 1	Mus musculus	162-165
33577850-4	2021	This study aimed to investigate whether GYY4137 inhibits the activation of the pyrin domain-containing protein 3 (NLRP3) inflammasome by inhibiting the PDGFRbeta/Akt/NF-kappaB pathway.	GYY 4137	40-47	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	166-175
33577850-10	2021	We discovered that GYY4137 reduced the levels of the p-PDGFRbeta, p-NF-kappaB, ASC, NLRP3, caspase-1, and p-Akt proteins in septic mouse lung tissue.	GYY 4137	19-26	platelet derived growth factor receptor, beta polypeptide	Mus musculus	55-64
33577850-10	2021	We discovered that GYY4137 reduced the levels of the p-PDGFRbeta, p-NF-kappaB, ASC, NLRP3, caspase-1, and p-Akt proteins in septic mouse lung tissue.	GYY 4137	19-26	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	68-77
33577850-10	2021	We discovered that GYY4137 reduced the levels of the p-PDGFRbeta, p-NF-kappaB, ASC, NLRP3, caspase-1, and p-Akt proteins in septic mouse lung tissue.	GYY 4137	19-26	steroid sulfatase	Mus musculus	79-82
33577850-10	2021	We discovered that GYY4137 reduced the levels of the p-PDGFRbeta, p-NF-kappaB, ASC, NLRP3, caspase-1, and p-Akt proteins in septic mouse lung tissue.	GYY 4137	19-26	NLR family, pyrin domain containing 3	Mus musculus	84-89
33577850-10	2021	We discovered that GYY4137 reduced the levels of the p-PDGFRbeta, p-NF-kappaB, ASC, NLRP3, caspase-1, and p-Akt proteins in septic mouse lung tissue.	GYY 4137	19-26	caspase 1	Mus musculus	91-100
33577850-10	2021	We discovered that GYY4137 reduced the levels of the p-PDGFRbeta, p-NF-kappaB, ASC, NLRP3, caspase-1, and p-Akt proteins in septic mouse lung tissue.	GYY 4137	19-26	thymoma viral proto-oncogene 1	Mus musculus	108-111
33529908-7	2021	Moreover, GYY4137 activated autophagy by upregulating the expression levels of the autophagy-related proteins LC3 and Beclin-1 and downregulating P62 in LPS-treated HPDLCs and inflamed periodontal tissues.	GYY 4137	10-17	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	110-113
33537813-8	2021	In the present study, treatment with either GYY4137 or transfection with GRP78 siRNA both suppressed the activation of p-P70S6k and p-mTOR.	GYY 4137	44-51	ribosomal protein S6 kinase B1	Rattus norvegicus	121-127
33537813-8	2021	In the present study, treatment with either GYY4137 or transfection with GRP78 siRNA both suppressed the activation of p-P70S6k and p-mTOR.	GYY 4137	44-51	mechanistic target of rapamycin kinase	Rattus norvegicus	134-138
33854181-5	2021	Here, we show that both recombinant and native rat Kv2.1 channels are inhibited by the H2S donors, NaHS and GYY4137.	GYY 4137	108-115	potassium voltage-gated channel subfamily B member 1	Rattus norvegicus	51-56
33529908-7	2021	Moreover, GYY4137 activated autophagy by upregulating the expression levels of the autophagy-related proteins LC3 and Beclin-1 and downregulating P62 in LPS-treated HPDLCs and inflamed periodontal tissues.	GYY 4137	10-17	beclin 1	Homo sapiens	118-126
33529908-7	2021	Moreover, GYY4137 activated autophagy by upregulating the expression levels of the autophagy-related proteins LC3 and Beclin-1 and downregulating P62 in LPS-treated HPDLCs and inflamed periodontal tissues.	GYY 4137	10-17	nucleoporin 62	Homo sapiens	146-149
33253721-7	2021	Meanwhile, GYY4137 could promote the proliferation (P < 0.01) and migration (P < 0.01) of HUVECs, increase the expression of endothelial NO synthase (eNOS) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) both in SHR and HUVECs treated with GYY4137.	GYY 4137	11-18	nitric oxide synthase 3	Rattus norvegicus	125-148
33841145-9	2021	Blockers of large-conductance calcium-activated (BKCa) and voltage-gated type 7 (KV7) potassium channels also inhibited GYY4137 relaxations.	GYY 4137	120-127	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	49-53
33673622-9	2021	Treatment of SELENBP1 knock-down cells with the H2S donor GYY4137 partially restored lipid accumulation, increased cellular H2S levels, and exerted a bell-shaped effect on cellular bioenergetics (enhancement at 1 and 3 mM, and inhibition at 6 mM).	GYY 4137	58-65	selenium binding protein 1	Homo sapiens	13-21
33253721-7	2021	Meanwhile, GYY4137 could promote the proliferation (P < 0.01) and migration (P < 0.01) of HUVECs, increase the expression of endothelial NO synthase (eNOS) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) both in SHR and HUVECs treated with GYY4137.	GYY 4137	11-18	nitric oxide synthase 3	Rattus norvegicus	150-154
33253721-7	2021	Meanwhile, GYY4137 could promote the proliferation (P < 0.01) and migration (P < 0.01) of HUVECs, increase the expression of endothelial NO synthase (eNOS) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) both in SHR and HUVECs treated with GYY4137.	GYY 4137	11-18	kinase insert domain receptor	Rattus norvegicus	160-205
33253721-7	2021	Meanwhile, GYY4137 could promote the proliferation (P < 0.01) and migration (P < 0.01) of HUVECs, increase the expression of endothelial NO synthase (eNOS) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) both in SHR and HUVECs treated with GYY4137.	GYY 4137	11-18	kinase insert domain receptor	Rattus norvegicus	207-213
33253721-8	2021	In addition to the above results, the PIP3/Akt signaling pathway was activated and the expression of caspase 3 was increased by GYY4137.	GYY 4137	128-135	AKT serine/threonine kinase 1	Rattus norvegicus	43-46
33253721-8	2021	In addition to the above results, the PIP3/Akt signaling pathway was activated and the expression of caspase 3 was increased by GYY4137.	GYY 4137	128-135	caspase 3	Rattus norvegicus	101-110
33253721-9	2021	However, all the above effects of GYY4137 were blocked by ZD6474 (a VEGFR2 inhibitor).	GYY 4137	34-41	kinase insert domain receptor	Rattus norvegicus	68-74
32219872-8	2021	Similarly, in carbon tetrachloride (CCl4 )-stimulated mice, GYY4137 increased Keap1 S-sulfhydration, improved liver function, alleviated liver fibrosis, decreased hepatic oxidative stress and activated the Nrf2 signaling pathway, and these effects were abrogated after Keap1 Cys151 mutation.	GYY 4137	60-67	chemokine (C-C motif) ligand 4	Mus musculus	36-40
32219872-8	2021	Similarly, in carbon tetrachloride (CCl4 )-stimulated mice, GYY4137 increased Keap1 S-sulfhydration, improved liver function, alleviated liver fibrosis, decreased hepatic oxidative stress and activated the Nrf2 signaling pathway, and these effects were abrogated after Keap1 Cys151 mutation.	GYY 4137	60-67	kelch-like ECH-associated protein 1	Mus musculus	78-83
32219872-3	2021	We showed that in streptozotocin (STZ)- and high-fat diet (HFD)-treated LDLr-/- mice, the H2 S donor GYY4137 ameliorated liver injury, decreased serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, mitigated lipid deposition and reduced hepatocyte death.	GYY 4137	101-108	low density lipoprotein receptor	Mus musculus	72-76
32219872-8	2021	Similarly, in carbon tetrachloride (CCl4 )-stimulated mice, GYY4137 increased Keap1 S-sulfhydration, improved liver function, alleviated liver fibrosis, decreased hepatic oxidative stress and activated the Nrf2 signaling pathway, and these effects were abrogated after Keap1 Cys151 mutation.	GYY 4137	60-67	nuclear factor, erythroid derived 2, like 2	Mus musculus	206-210
32219872-8	2021	Similarly, in carbon tetrachloride (CCl4 )-stimulated mice, GYY4137 increased Keap1 S-sulfhydration, improved liver function, alleviated liver fibrosis, decreased hepatic oxidative stress and activated the Nrf2 signaling pathway, and these effects were abrogated after Keap1 Cys151 mutation.	GYY 4137	60-67	kelch-like ECH-associated protein 1	Mus musculus	269-274
32219872-3	2021	We showed that in streptozotocin (STZ)- and high-fat diet (HFD)-treated LDLr-/- mice, the H2 S donor GYY4137 ameliorated liver injury, decreased serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, mitigated lipid deposition and reduced hepatocyte death.	GYY 4137	101-108	glutamic--pyruvic transaminase	Homo sapiens	151-175
32219872-11	2021	Hence, administration of exogenous H2 S in the form of the H2 S donor GYY4137 may be of therapeutic benefit in the context of concurrent hyperlipidemia and hyperglycemia-induced or CCl4 -stimulated liver dysfunction.	GYY 4137	70-77	C-C motif chemokine ligand 4	Homo sapiens	181-185
32219872-3	2021	We showed that in streptozotocin (STZ)- and high-fat diet (HFD)-treated LDLr-/- mice, the H2 S donor GYY4137 ameliorated liver injury, decreased serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, mitigated lipid deposition and reduced hepatocyte death.	GYY 4137	101-108	solute carrier family 17 member 5	Homo sapiens	186-212
32219872-3	2021	We showed that in streptozotocin (STZ)- and high-fat diet (HFD)-treated LDLr-/- mice, the H2 S donor GYY4137 ameliorated liver injury, decreased serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, mitigated lipid deposition and reduced hepatocyte death.	GYY 4137	101-108	solute carrier family 17 member 5	Homo sapiens	214-217
33246971-8	2021	Incubation with the slow-releasing H2S donor GYY4137 alleviated the defects of brain vascular development in cbs and cth morphants.	GYY 4137	45-52	cystathionase (cystathionine gamma-lyase)	Danio rerio	117-120
33372981-8	2020	Diabetes-induced increase in oxidative stress, MMP-9 activation, and mitochondrial damage were also attenuated in mice receiving GYY4137.	GYY 4137	129-136	matrix metallopeptidase 9	Mus musculus	47-52
32144792-0	2020	GYY4137 exhibits anti-atherosclerosis effect in apolipoprotein E(-/-)mice via PI3K/Akt and TLR4 signaling.	GYY 4137	0-7	apolipoprotein E	Mus musculus	48-64
33276365-2	2020	Hsp70 and GYY4137 have been shown to significantly reduce LPS-induced production of inflammatory mediators by SH-SY5Y cells, including reactive oxygen species, nitric oxide, TNFalpha, IL-1beta, and IL-6.	GYY 4137	10-17	tumor necrosis factor	Homo sapiens	174-182
33276365-2	2020	Hsp70 and GYY4137 have been shown to significantly reduce LPS-induced production of inflammatory mediators by SH-SY5Y cells, including reactive oxygen species, nitric oxide, TNFalpha, IL-1beta, and IL-6.	GYY 4137	10-17	interleukin 1 alpha	Homo sapiens	184-192
33276365-2	2020	Hsp70 and GYY4137 have been shown to significantly reduce LPS-induced production of inflammatory mediators by SH-SY5Y cells, including reactive oxygen species, nitric oxide, TNFalpha, IL-1beta, and IL-6.	GYY 4137	10-17	interleukin 6	Homo sapiens	198-202
33114185-12	2020	Additionally, a single GYY4137 injection improved oral glucose tolerance in WD-fed male mice and also enhanced glucose-stimulated GLP-1 release.	GYY 4137	23-30	glucagon	Mus musculus	130-135
32664399-2	2020	GYY4137 specifically potentiated TGF-beta expression and production in dendritic cells and significantly reduced IFN-gamma and IL-17 production in the lymph node and spinal cord T cells obtained from mice immunized with CNS antigens.	GYY 4137	0-7	transforming growth factor alpha	Mus musculus	33-41
32664399-2	2020	GYY4137 specifically potentiated TGF-beta expression and production in dendritic cells and significantly reduced IFN-gamma and IL-17 production in the lymph node and spinal cord T cells obtained from mice immunized with CNS antigens.	GYY 4137	0-7	interferon gamma	Mus musculus	113-122
32664399-2	2020	GYY4137 specifically potentiated TGF-beta expression and production in dendritic cells and significantly reduced IFN-gamma and IL-17 production in the lymph node and spinal cord T cells obtained from mice immunized with CNS antigens.	GYY 4137	0-7	interleukin 17A	Mus musculus	127-132
32664399-3	2020	Both the proportion of FoxP3+ regulatory CD4+ T cells in the lymph node cells, and the percentage of IL-17+ CD4+ T cells in the spinal cord cells were reduced upon culturing with GYY4137.	GYY 4137	179-186	forkhead box P3	Homo sapiens	23-28
32664399-3	2020	Both the proportion of FoxP3+ regulatory CD4+ T cells in the lymph node cells, and the percentage of IL-17+ CD4+ T cells in the spinal cord cells were reduced upon culturing with GYY4137.	GYY 4137	179-186	CD4 molecule	Homo sapiens	41-44
32664399-3	2020	Both the proportion of FoxP3+ regulatory CD4+ T cells in the lymph node cells, and the percentage of IL-17+ CD4+ T cells in the spinal cord cells were reduced upon culturing with GYY4137.	GYY 4137	179-186	interleukin 17A	Mus musculus	101-106
32664399-3	2020	Both the proportion of FoxP3+ regulatory CD4+ T cells in the lymph node cells, and the percentage of IL-17+ CD4+ T cells in the spinal cord cells were reduced upon culturing with GYY4137.	GYY 4137	179-186	CD4 molecule	Homo sapiens	108-111
32144792-0	2020	GYY4137 exhibits anti-atherosclerosis effect in apolipoprotein E(-/-)mice via PI3K/Akt and TLR4 signaling.	GYY 4137	0-7	thymoma viral proto-oncogene 1	Mus musculus	83-86
32144792-0	2020	GYY4137 exhibits anti-atherosclerosis effect in apolipoprotein E(-/-)mice via PI3K/Akt and TLR4 signaling.	GYY 4137	0-7	toll-like receptor 4	Mus musculus	91-95
32144792-3	2020	In the ApoE-/- mice fed with high-fat diet, daily GYY4137 administration for 8 weeks effectively decreased cartiod atherosclerotic plaque area and the volume of foam cells, regulated of lipid metabolism, and down-regulated the pro-inflammatory cytokines levels, up-regulated the anti-inflammatory cytokines levels.	GYY 4137	50-57	apolipoprotein E	Mus musculus	7-11
32144792-5	2020	Furthermore, our studies showed that GYY4137 could activate PI3K/Akt signaling pathway and consequently reduce the expression of TLR4: to be critical for foam cell formation, preventing atherosclerotic plaque formation and destabilization.	GYY 4137	37-44	thymoma viral proto-oncogene 1	Mus musculus	65-68
32144792-5	2020	Furthermore, our studies showed that GYY4137 could activate PI3K/Akt signaling pathway and consequently reduce the expression of TLR4: to be critical for foam cell formation, preventing atherosclerotic plaque formation and destabilization.	GYY 4137	37-44	toll-like receptor 4	Mus musculus	129-133
32157318-9	2020	The pre-treatment with GYY4137 resulted in a drastic down-regulation of many TNF-alpha effectors that are induced by LPS treatment in THP-1 cells.	GYY 4137	23-30	tumor necrosis factor	Homo sapiens	77-86
32695008-9	2020	GYY4137 treatment markedly activated SIRT1 signaling and ameliorated lung IR injury in type 2 DM animals by improving lung functional recovery, diminishing oxidative damage, reducing inflammation, and suppressing cell apoptosis.	GYY 4137	0-7	sirtuin 1	Rattus norvegicus	37-42
32695008-11	2020	Additionally, treatment with GYY4137 significantly activated the Nrf2/HO-1 antioxidant signaling pathway and increased eNOS phosphorylation.	GYY 4137	29-36	NFE2 like bZIP transcription factor 2	Rattus norvegicus	65-69
32695008-11	2020	Additionally, treatment with GYY4137 significantly activated the Nrf2/HO-1 antioxidant signaling pathway and increased eNOS phosphorylation.	GYY 4137	29-36	heme oxygenase 1	Rattus norvegicus	70-74
32695008-11	2020	Additionally, treatment with GYY4137 significantly activated the Nrf2/HO-1 antioxidant signaling pathway and increased eNOS phosphorylation.	GYY 4137	29-36	nitric oxide synthase 3	Rattus norvegicus	119-123
32695008-13	2020	Together, our results indicate that GYY4137 treatment effectively attenuated lung IR injury under type 2 diabetic conditions via activation of lung SIRT1 signaling.	GYY 4137	36-43	sirtuin 1	Rattus norvegicus	148-153
32157318-9	2020	The pre-treatment with GYY4137 resulted in a drastic down-regulation of many TNF-alpha effectors that are induced by LPS treatment in THP-1 cells.	GYY 4137	23-30	GLI family zinc finger 2	Homo sapiens	134-139
31119834-10	2019	In vivo treatment with NaHS or GYY4137 inhibited the spontaneous contractions and upregulated TLR2 expression.	GYY 4137	31-38	toll-like receptor 2	Mus musculus	94-98
32337694-7	2020	The expression of Caspase-3 and Bax turned out to be strengthened by T/ D and relatively decreased with GYY4137 treatment in both the G-IP and G-IT groups.	GYY 4137	104-111	caspase 3	Rattus norvegicus	18-27
32337694-7	2020	The expression of Caspase-3 and Bax turned out to be strengthened by T/ D and relatively decreased with GYY4137 treatment in both the G-IP and G-IT groups.	GYY 4137	104-111	BCL2 associated X, apoptosis regulator	Rattus norvegicus	32-35
32337694-8	2020	Moreover, the Bcl-2 expression was inhibited in the T/D group, and promoted by GYY4137 in the G-IP and G-IT groups.	GYY 4137	79-86	BCL2, apoptosis regulator	Rattus norvegicus	14-19
31737669-9	2019	Conclusion: Taken together, this research suggests that GYY4137 preserves the intestinal barrier from SDC-induced injury via suppressing the activation of P-MLCK-P-MLC2 signaling pathway and increasing the expression level of tight junctions.	GYY 4137	56-63	myosin light chain kinase 3	Mus musculus	157-161
31737669-9	2019	Conclusion: Taken together, this research suggests that GYY4137 preserves the intestinal barrier from SDC-induced injury via suppressing the activation of P-MLCK-P-MLC2 signaling pathway and increasing the expression level of tight junctions.	GYY 4137	56-63	myosin, light polypeptide 2, regulatory, cardiac, slow	Mus musculus	164-168
31551776-11	2019	Increased myeloperoxidase activity, plasma extravasation, and subcutaneous MIP-2 levels of hind paws were detected in TRPA1 knockout mice upon GYY4137 treatment.	GYY 4137	143-150	myeloperoxidase	Mus musculus	10-25
31551776-11	2019	Increased myeloperoxidase activity, plasma extravasation, and subcutaneous MIP-2 levels of hind paws were detected in TRPA1 knockout mice upon GYY4137 treatment.	GYY 4137	143-150	chemokine (C-X-C motif) ligand 2	Mus musculus	75-80
31551776-11	2019	Increased myeloperoxidase activity, plasma extravasation, and subcutaneous MIP-2 levels of hind paws were detected in TRPA1 knockout mice upon GYY4137 treatment.	GYY 4137	143-150	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	118-123
31551776-13	2019	TRPA1 WT animals exhibited smaller cartilage destruction upon GYY4137 administration.	GYY 4137	62-69	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	0-5
31551776-17	2019	According to our data, the protective effect of GYY4137 is mediated by TRPA1, while detrimental actions are independent of the ion channel in the K/BxN serum-transfer arthritis model in mice.	GYY 4137	48-55	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	71-76
31943384-7	2020	The expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) that stimulated by wear particles were significantly reduced by GYY4137.	GYY 4137	178-185	tumor necrosis factor	Homo sapiens	18-45
31943384-7	2020	The expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) that stimulated by wear particles were significantly reduced by GYY4137.	GYY 4137	178-185	tumor necrosis factor	Homo sapiens	47-56
31943384-7	2020	The expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) that stimulated by wear particles were significantly reduced by GYY4137.	GYY 4137	178-185	interleukin 1 beta	Homo sapiens	59-76
31943384-7	2020	The expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) that stimulated by wear particles were significantly reduced by GYY4137.	GYY 4137	178-185	interleukin 1 beta	Homo sapiens	78-86
31943384-7	2020	The expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) that stimulated by wear particles were significantly reduced by GYY4137.	GYY 4137	178-185	interleukin 6	Homo sapiens	93-106
31943384-7	2020	The expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) that stimulated by wear particles were significantly reduced by GYY4137.	GYY 4137	178-185	interleukin 6	Homo sapiens	108-112
31943384-10	2020	Cotreated macrophages with GYY4137 in part reversed the decline of SIRT1.	GYY 4137	27-34	sirtuin 1	Homo sapiens	67-72
31943384-11	2020	More importantly, with the SIRT1 recombinant lentivirus and small interfering RNAs (siRNA) against SIRT1, our data indicated that SIRT1 mediated the inhibitory effects of GYY4137 on wear debris-induced inflammation.	GYY 4137	171-178	sirtuin 1	Homo sapiens	27-32
31943384-11	2020	More importantly, with the SIRT1 recombinant lentivirus and small interfering RNAs (siRNA) against SIRT1, our data indicated that SIRT1 mediated the inhibitory effects of GYY4137 on wear debris-induced inflammation.	GYY 4137	171-178	sirtuin 1	Homo sapiens	99-104
31943384-11	2020	More importantly, with the SIRT1 recombinant lentivirus and small interfering RNAs (siRNA) against SIRT1, our data indicated that SIRT1 mediated the inhibitory effects of GYY4137 on wear debris-induced inflammation.	GYY 4137	171-178	sirtuin 1	Homo sapiens	99-104
32924989-9	2020	RESULTS: GYY treatment significantly reduced the expression of E-selectin and ICAM-1 but not of VCAM-1.	GYY 4137	9-12	selectin E	Homo sapiens	63-73
32924989-9	2020	RESULTS: GYY treatment significantly reduced the expression of E-selectin and ICAM-1 but not of VCAM-1.	GYY 4137	9-12	intercellular adhesion molecule 1	Homo sapiens	78-84
31366822-10	2019	The addition of GYY4137 inhibited HG-induced upregulation of MMP14 expression.	GYY 4137	16-23	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	61-66
31616516-8	2019	Furthermore, STAT3 siRNA transfection and GYY4137 pretreatment combined attenuated HG-induced apoptosis as illustrated by the decrease in the number of terminal deoxynucleotidyl transferase dUTP nick end labeling-positive cells, caspase-3 activity, apoptosis ratio and BCL2 associated X, apoptosis regulator/BCL2 apoptosis regulator ratio in H9c2 cells.	GYY 4137	42-49	caspase 3	Rattus norvegicus	229-238
31616516-8	2019	Furthermore, STAT3 siRNA transfection and GYY4137 pretreatment combined attenuated HG-induced apoptosis as illustrated by the decrease in the number of terminal deoxynucleotidyl transferase dUTP nick end labeling-positive cells, caspase-3 activity, apoptosis ratio and BCL2 associated X, apoptosis regulator/BCL2 apoptosis regulator ratio in H9c2 cells.	GYY 4137	42-49	BCL2, apoptosis regulator	Rattus norvegicus	269-332
31616516-9	2019	In addition, STAT3 siRNA transfection and GYY4137 blocked HG-induced oxidative stress as evidenced by the decrease in reactive oxygen species generation, malondialdehyde content and NADPH oxidase 2 expression, and the increase in superoxide dismutase activity and glutathione level.	GYY 4137	42-49	cytochrome b-245 beta chain	Rattus norvegicus	182-197
31616516-10	2019	Notably, GYY4137 pretreatment was revealed to reduce the p-STAT3/STAT3 ratio and HIF-1alpha protein expression, resulting in the inhibition of the STAT3/HIF-1alpha signaling pathway in HG-treated H9c2 cells.	GYY 4137	9-16	signal transducer and activator of transcription 3	Rattus norvegicus	59-64
31616516-10	2019	Notably, GYY4137 pretreatment was revealed to reduce the p-STAT3/STAT3 ratio and HIF-1alpha protein expression, resulting in the inhibition of the STAT3/HIF-1alpha signaling pathway in HG-treated H9c2 cells.	GYY 4137	9-16	signal transducer and activator of transcription 3	Rattus norvegicus	65-70
31616516-10	2019	Notably, GYY4137 pretreatment was revealed to reduce the p-STAT3/STAT3 ratio and HIF-1alpha protein expression, resulting in the inhibition of the STAT3/HIF-1alpha signaling pathway in HG-treated H9c2 cells.	GYY 4137	9-16	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	81-91
31616516-10	2019	Notably, GYY4137 pretreatment was revealed to reduce the p-STAT3/STAT3 ratio and HIF-1alpha protein expression, resulting in the inhibition of the STAT3/HIF-1alpha signaling pathway in HG-treated H9c2 cells.	GYY 4137	9-16	signal transducer and activator of transcription 3	Rattus norvegicus	65-70
31616516-10	2019	Notably, GYY4137 pretreatment was revealed to reduce the p-STAT3/STAT3 ratio and HIF-1alpha protein expression, resulting in the inhibition of the STAT3/HIF-1alpha signaling pathway in HG-treated H9c2 cells.	GYY 4137	9-16	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	153-163
31719759-0	2019	Increased circulating peroxiredoxin-4 in sepsis model rats involves secretion from hepatocytes and is mitigated by GYY4137.	GYY 4137	115-122	peroxiredoxin 4	Rattus norvegicus	22-37
31719759-10	2019	An increase in plasma Prx4 level caused by LPS was observed, but the increase was attenuated by pre-administration of GYY4137.	GYY 4137	118-125	peroxiredoxin 4	Rattus norvegicus	22-26
31719759-12	2019	GYY4137 attenuated the IL-1beta-induced Prx4 secretion from hepatocytes.	GYY 4137	0-7	interleukin 1 beta	Rattus norvegicus	23-31
31719759-12	2019	GYY4137 attenuated the IL-1beta-induced Prx4 secretion from hepatocytes.	GYY 4137	0-7	peroxiredoxin 4	Rattus norvegicus	40-44
31719759-14	2019	GYY4137 attenuates not only hepatic injury but also Prx4 secretion.	GYY 4137	0-7	peroxiredoxin 4	Rattus norvegicus	52-56
31551776-0	2019	TRPA1 Ion Channel Determines Beneficial and Detrimental Effects of GYY4137 in Murine Serum-Transfer Arthritis.	GYY 4137	67-74	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	0-5
31551776-2	2019	The present study aims to investigate TRPA1-mediated effects of sulfide donor GYY4137 in K/BxN serum-transfer arthritis, a rodent model of rheumatoid arthritis.	GYY 4137	78-85	transient receptor potential cation channel subfamily A member 1	Homo sapiens	38-43
31551776-9	2019	GYY4137 aggravated mechanical hyperalgesia in TRPA1 knockout mice but ameliorated it in wild-type ones.	GYY 4137	0-7	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	46-51
31551776-10	2019	Arthritis score was lowered by GYY4137 in TRPA1 wild-type animals.	GYY 4137	31-38	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	42-47
31085234-11	2019	Interestingly, GYY4137 or AS1842856 treatment prevented these changes by modulating Akt/FOXO1 axis in HHcy.	GYY 4137	15-22	AKT serine/threonine kinase 1	Homo sapiens	84-87
31085234-11	2019	Interestingly, GYY4137 or AS1842856 treatment prevented these changes by modulating Akt/FOXO1 axis in HHcy.	GYY 4137	15-22	forkhead box O1	Homo sapiens	88-93
31085234-12	2019	We conclude that GYY4137 and/or AS1842856 mitigates HHcy induced mesangial cell damage and ECM remodelling by regulating Akt/FOXO1 pathway.	GYY 4137	17-24	AKT serine/threonine kinase 1	Homo sapiens	121-124
31085234-12	2019	We conclude that GYY4137 and/or AS1842856 mitigates HHcy induced mesangial cell damage and ECM remodelling by regulating Akt/FOXO1 pathway.	GYY 4137	17-24	forkhead box O1	Homo sapiens	125-130
32305963-3	2019	Here we report that GYY4137, a H 2S donor, reduced the plaque formation of aortic roots and the levels of both intercellular cell adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) in diabetes-accelerated atherosclerotic cells and mouse models.	GYY 4137	20-27	intercellular adhesion molecule 1	Mus musculus	111-149
32305963-3	2019	Here we report that GYY4137, a H 2S donor, reduced the plaque formation of aortic roots and the levels of both intercellular cell adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) in diabetes-accelerated atherosclerotic cells and mouse models.	GYY 4137	20-27	intercellular adhesion molecule 1	Mus musculus	151-156
32305963-3	2019	Here we report that GYY4137, a H 2S donor, reduced the plaque formation of aortic roots and the levels of both intercellular cell adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) in diabetes-accelerated atherosclerotic cells and mouse models.	GYY 4137	20-27	vascular cell adhesion molecule 1	Mus musculus	162-195
32305963-3	2019	Here we report that GYY4137, a H 2S donor, reduced the plaque formation of aortic roots and the levels of both intercellular cell adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) in diabetes-accelerated atherosclerotic cells and mouse models.	GYY 4137	20-27	vascular cell adhesion molecule 1	Mus musculus	197-202
32305963-4	2019	The inflammatory factors of TNF-alpha, IL-1beta, IL-6, and MCP1 were also significantly reduced by GYY4137.	GYY 4137	99-106	tumor necrosis factor	Mus musculus	28-37
32305963-4	2019	The inflammatory factors of TNF-alpha, IL-1beta, IL-6, and MCP1 were also significantly reduced by GYY4137.	GYY 4137	99-106	interleukin 1 alpha	Mus musculus	39-47
32305963-4	2019	The inflammatory factors of TNF-alpha, IL-1beta, IL-6, and MCP1 were also significantly reduced by GYY4137.	GYY 4137	99-106	interleukin 6	Mus musculus	49-53
32305963-4	2019	The inflammatory factors of TNF-alpha, IL-1beta, IL-6, and MCP1 were also significantly reduced by GYY4137.	GYY 4137	99-106	mast cell protease 1	Mus musculus	59-63
32305963-5	2019	Mechanically, GYY4137 suppressed the activation of pyrin domain containing protein 3 (NLRP3) inflammasome in diabetes-accelerated atherosclerosis conditions.	GYY 4137	14-21	pyrin domain-containing protein 3	Mus musculus	51-84
32305963-5	2019	Mechanically, GYY4137 suppressed the activation of pyrin domain containing protein 3 (NLRP3) inflammasome in diabetes-accelerated atherosclerosis conditions.	GYY 4137	14-21	NLR family, pyrin domain containing 3	Mus musculus	86-91
32373293-10	2019	Conclusion: Our data demonstrated that GYY4137 may alleviate the sperm damage and epididymis injury in experimentally VC-induced rats by activation of the PI3K/Akt pathway.	GYY 4137	39-46	AKT serine/threonine kinase 1	Rattus norvegicus	160-163
30870598-5	2019	In HLS group, GYY4137 treatment significantly increased levels of osteocalcin in sera.	GYY 4137	14-21	bone gamma-carboxyglutamate protein	Rattus norvegicus	66-77
30870598-7	2019	In MC3T3-E1 cells exposed to modeled microgravity, GYY4137 stimulated transcriptional levels of runt-related transcription factor 2 and enhanced osteoblastic differentiation, as evidenced by increased mRNA expression and activity of alkaline phosphatase.	GYY 4137	51-58	runt related transcription factor 2	Mus musculus	96-131
30870598-8	2019	HLS in rats led to enhanced levels of interleukin 6 in sera, skeletal muscle, and tibiae, which could be attenuated by GYY4137 treatment.	GYY 4137	119-126	interleukin 6	Rattus norvegicus	38-51
32373293-0	2019	GYY4137 a H2S donor, attenuates ipsilateral epididymis injury in experimentally varicocele-induced rats via activation of the PI3K/Akt pathway.	GYY 4137	0-7	AKT serine/threonine kinase 1	Rattus norvegicus	131-134
32373293-9	2019	In addition, treatment with GYY4137 obviously reduced the levels of caspase-3 and Bax and increased the levels of the phosphorylation of PI3K p85 and Akt.	GYY 4137	28-35	caspase 3	Rattus norvegicus	68-77
30849492-1	2019	We explored possibility that sodium/calcium exchanger 1 (NCX1) is involved in pH modulation and apoptosis induction in GYY4137 treated cells.	GYY 4137	119-126	solute carrier family 8 member A1	Homo sapiens	29-55
32373293-9	2019	In addition, treatment with GYY4137 obviously reduced the levels of caspase-3 and Bax and increased the levels of the phosphorylation of PI3K p85 and Akt.	GYY 4137	28-35	BCL2 associated X, apoptosis regulator	Rattus norvegicus	82-85
32373293-9	2019	In addition, treatment with GYY4137 obviously reduced the levels of caspase-3 and Bax and increased the levels of the phosphorylation of PI3K p85 and Akt.	GYY 4137	28-35	AKT serine/threonine kinase 1	Rattus norvegicus	150-153
30849492-1	2019	We explored possibility that sodium/calcium exchanger 1 (NCX1) is involved in pH modulation and apoptosis induction in GYY4137 treated cells.	GYY 4137	119-126	solute carrier family 8 member A1	Homo sapiens	57-61
30849492-4	2019	We observed increased mRNA and protein expression of both, NCX1 and sodium/hydrogen exchanger 1 (NHE1) in DLD1-induced tumors from GYY4137-treated mice.	GYY 4137	131-138	solute carrier family 8 (sodium/calcium exchanger), member 1	Mus musculus	59-63
30849492-4	2019	We observed increased mRNA and protein expression of both, NCX1 and sodium/hydrogen exchanger 1 (NHE1) in DLD1-induced tumors from GYY4137-treated mice.	GYY 4137	131-138	solute carrier family 9 (sodium/hydrogen exchanger), member 1	Mus musculus	68-95
30849492-4	2019	We observed increased mRNA and protein expression of both, NCX1 and sodium/hydrogen exchanger 1 (NHE1) in DLD1-induced tumors from GYY4137-treated mice.	GYY 4137	131-138	solute carrier family 9 (sodium/hydrogen exchanger), member 1	Mus musculus	97-101
30849492-5	2019	NCX1 was coupled with NHE1 in A2780 and DLD1 cells and this complex partially disintegrated after GYY4137 treatment.	GYY 4137	98-105	solute carrier family 8 member A1	Homo sapiens	0-4
30849492-5	2019	NCX1 was coupled with NHE1 in A2780 and DLD1 cells and this complex partially disintegrated after GYY4137 treatment.	GYY 4137	98-105	solute carrier family 9 member A1	Homo sapiens	22-26
31131233-7	2019	Unlike CBS, cystathionine-gamma lyase (CSE), methylenetetrahydrofolate reductase (MTHFR) levels which were reduced but compensated by GYY4137 intervention.	GYY 4137	134-141	methylenetetrahydrofolate reductase	Mus musculus	82-87
30862476-8	2019	Subsequent in vitro studies implicated a role of CSE-derived H2S for keratinocyte differentiation: the H2S-donor GYY4137 markedly increased the Ca2+-triggered expression of the early keratinocyte differentiation markers cytokeratin 10 (CK10) and involucrin (IVN) in cultured human keratinocytes.	GYY 4137	113-120	cystathionase (cystathionine gamma-lyase)	Mus musculus	49-52
30862476-8	2019	Subsequent in vitro studies implicated a role of CSE-derived H2S for keratinocyte differentiation: the H2S-donor GYY4137 markedly increased the Ca2+-triggered expression of the early keratinocyte differentiation markers cytokeratin 10 (CK10) and involucrin (IVN) in cultured human keratinocytes.	GYY 4137	113-120	keratin 10	Homo sapiens	220-234
30862476-8	2019	Subsequent in vitro studies implicated a role of CSE-derived H2S for keratinocyte differentiation: the H2S-donor GYY4137 markedly increased the Ca2+-triggered expression of the early keratinocyte differentiation markers cytokeratin 10 (CK10) and involucrin (IVN) in cultured human keratinocytes.	GYY 4137	113-120	keratin 10	Homo sapiens	236-240
30862476-9	2019	Here, GYY4137-derived H2S strongly enhanced CK10 expression by increasing the binding of RNA polymerase II to the CK10 promoter.	GYY 4137	6-13	keratin 10	Homo sapiens	44-48
30862476-9	2019	Here, GYY4137-derived H2S strongly enhanced CK10 expression by increasing the binding of RNA polymerase II to the CK10 promoter.	GYY 4137	6-13	keratin 10	Homo sapiens	114-118
31131233-9	2019	Increased glutamate levels in CBS+/- strain were prominent than WT mice and these mice also exhibited higher IOP that was lowered by GYY4137 treatment.	GYY 4137	133-140	cystathionine beta-synthase	Mus musculus	30-33
31131233-11	2019	Interestingly, GYY4137 was able to improve CBS+/- mice behavior together with lowering their glutamate levels.	GYY 4137	15-22	cystathionine beta-synthase	Mus musculus	43-46
31131233-12	2019	Blood-retinal barrier (BRB) appeared compromised in CBS+/- with vessels" leakage that was mitigated in GYY4137 treated group.	GYY 4137	103-110	cystathionine beta-synthase	Mus musculus	52-55
30842737-10	2019	GYY4137 and ATB-346 significantly reduced the IM-induced increase in muscular myeloperoxidase (MPO) activity and protein levels of interleukin (IL)-6, IL-1beta and monocyte chemotactic protein 1; the reduction by naproxen was less pronounced and only reached significance for MPO activity and IL-6 levels.	GYY 4137	0-7	myeloperoxidase	Homo sapiens	78-93
30370692-3	2019	Here, we investigated the effects of two H 2 S donors sodium hydrosulfide and GYY4137 on the expression of ferroportin-1 (Fpn1), transferrin receptor-1 (TfR1), hepcidin, IL-6 and pSTAT3 in the spleen of mice in vivo and peritoneal macrophage in vitro.	GYY 4137	78-85	solute carrier family 40 (iron-regulated transporter), member 1	Mus musculus	107-120
30370692-3	2019	Here, we investigated the effects of two H 2 S donors sodium hydrosulfide and GYY4137 on the expression of ferroportin-1 (Fpn1), transferrin receptor-1 (TfR1), hepcidin, IL-6 and pSTAT3 in the spleen of mice in vivo and peritoneal macrophage in vitro.	GYY 4137	78-85	solute carrier family 40 (iron-regulated transporter), member 1	Mus musculus	122-126
30370692-3	2019	Here, we investigated the effects of two H 2 S donors sodium hydrosulfide and GYY4137 on the expression of ferroportin-1 (Fpn1), transferrin receptor-1 (TfR1), hepcidin, IL-6 and pSTAT3 in the spleen of mice in vivo and peritoneal macrophage in vitro.	GYY 4137	78-85	transferrin receptor	Mus musculus	129-151
30370692-3	2019	Here, we investigated the effects of two H 2 S donors sodium hydrosulfide and GYY4137 on the expression of ferroportin-1 (Fpn1), transferrin receptor-1 (TfR1), hepcidin, IL-6 and pSTAT3 in the spleen of mice in vivo and peritoneal macrophage in vitro.	GYY 4137	78-85	transferrin receptor	Mus musculus	153-157
30370692-3	2019	Here, we investigated the effects of two H 2 S donors sodium hydrosulfide and GYY4137 on the expression of ferroportin-1 (Fpn1), transferrin receptor-1 (TfR1), hepcidin, IL-6 and pSTAT3 in the spleen of mice in vivo and peritoneal macrophage in vitro.	GYY 4137	78-85	hepcidin antimicrobial peptide	Mus musculus	160-168
30842737-10	2019	GYY4137 and ATB-346 significantly reduced the IM-induced increase in muscular myeloperoxidase (MPO) activity and protein levels of interleukin (IL)-6, IL-1beta and monocyte chemotactic protein 1; the reduction by naproxen was less pronounced and only reached significance for MPO activity and IL-6 levels.	GYY 4137	0-7	myeloperoxidase	Homo sapiens	95-98
30842737-10	2019	GYY4137 and ATB-346 significantly reduced the IM-induced increase in muscular myeloperoxidase (MPO) activity and protein levels of interleukin (IL)-6, IL-1beta and monocyte chemotactic protein 1; the reduction by naproxen was less pronounced and only reached significance for MPO activity and IL-6 levels.	GYY 4137	0-7	interleukin 1 beta	Homo sapiens	151-159
30842737-10	2019	GYY4137 and ATB-346 significantly reduced the IM-induced increase in muscular myeloperoxidase (MPO) activity and protein levels of interleukin (IL)-6, IL-1beta and monocyte chemotactic protein 1; the reduction by naproxen was less pronounced and only reached significance for MPO activity and IL-6 levels.	GYY 4137	0-7	C-C motif chemokine ligand 2	Homo sapiens	164-194
30842737-10	2019	GYY4137 and ATB-346 significantly reduced the IM-induced increase in muscular myeloperoxidase (MPO) activity and protein levels of interleukin (IL)-6, IL-1beta and monocyte chemotactic protein 1; the reduction by naproxen was less pronounced and only reached significance for MPO activity and IL-6 levels.	GYY 4137	0-7	myeloperoxidase	Homo sapiens	276-279
30842737-10	2019	GYY4137 and ATB-346 significantly reduced the IM-induced increase in muscular myeloperoxidase (MPO) activity and protein levels of interleukin (IL)-6, IL-1beta and monocyte chemotactic protein 1; the reduction by naproxen was less pronounced and only reached significance for MPO activity and IL-6 levels.	GYY 4137	0-7	interleukin 6	Homo sapiens	293-297
30842737-11	2019	All treatments significantly reduced the increase in COX-2 activity caused by IM, whereas only GYY4137 significantly reduced the increase in iNOS activity.	GYY 4137	95-102	nitric oxide synthase 2	Homo sapiens	141-145
30036087-7	2019	GYY4137, a slow H2S donor, markedly improved urine concentration and prevented the down-regulation of renal AQP-2 protein expression in mice with lithium-induced nephrogenic diabetes insipidus (NDI).	GYY 4137	0-7	aquaporin 2	Homo sapiens	108-113
30605726-0	2019	GYY4137 attenuates LPS-induced acute lung injury via heme oxygenase-1 modulation.	GYY 4137	0-7	heme oxygenase 1	Mus musculus	53-69
30605726-3	2019	This study investigated the role of GYY4137 in acute lung injury (ALI) via HO-1 regulation.	GYY 4137	36-43	heme oxygenase 1	Mus musculus	75-79
30605726-5	2019	GYY4137 reduced the LPS-mediated pulmonary injury and neutrophil infiltration, and inhibited the LPS-induced production of proinflammatory cytokines, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression.	GYY 4137	0-7	nitric oxide synthase 2, inducible	Mus musculus	150-181
30605726-5	2019	GYY4137 reduced the LPS-mediated pulmonary injury and neutrophil infiltration, and inhibited the LPS-induced production of proinflammatory cytokines, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression.	GYY 4137	0-7	nitric oxide synthase 2, inducible	Mus musculus	183-187
30605726-5	2019	GYY4137 reduced the LPS-mediated pulmonary injury and neutrophil infiltration, and inhibited the LPS-induced production of proinflammatory cytokines, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression.	GYY 4137	0-7	prostaglandin-endoperoxide synthase 2	Mus musculus	193-209
30605726-5	2019	GYY4137 reduced the LPS-mediated pulmonary injury and neutrophil infiltration, and inhibited the LPS-induced production of proinflammatory cytokines, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression.	GYY 4137	0-7	prostaglandin-endoperoxide synthase 2	Mus musculus	211-216
30605726-7	2019	GYY4137, not time-expired GYY4137 significantly induced HO-1 expression compared with the LPS group.	GYY 4137	0-7	heme oxygenase 1	Mus musculus	56-60
30605726-8	2019	The beneficial effects of GYY4137 above were reversed by the HO-1 inhibitor tin protoporphyrin (SnPP).	GYY 4137	26-33	heme oxygenase 1	Mus musculus	61-65
30605726-9	2019	These results suggest an anti-inflammatory effect and a therapeutic role of GYY4137 in LPS-induced ALI via HO-1 regulation.	GYY 4137	76-83	heme oxygenase 1	Mus musculus	107-111
30527488-3	2019	We hypothesized that administration of GYY4137 would improve mesenteric perfusion, reduce intestinal injury, and reduce inflammatory responses in experimental NEC and ischemia-reperfusion injury, and that these benefits would be mediated through endothelial nitric oxide synthase-dependent pathways.	GYY 4137	39-46	nitric oxide synthase 3, endothelial cell	Mus musculus	246-279
30527488-15	2019	Cytokine expression after GYY4137 administration was altered by the ablation of eNOS in both NEC and I/R injury groups, with significant differences noted in Interleukin 6 and vascular endothelial growth factor.	GYY 4137	26-33	interleukin 6	Mus musculus	158-171
29343087-4	2019	Results: In ApoE-knockout atherosclerosis mice, treatment with an H2S donor (NaHS or GYY4137) reduced atherosclerotic plaque area, macrophage infiltration, aortic inflammation, and plasma lipid level.	GYY 4137	85-92	apolipoprotein E	Mus musculus	12-16
30279441-7	2018	In vitro, GYY4137 did not exert toxic effects on Hoxb8 neutrophils, but prevented their transmigration through an endothelial barrier in the presence and absence of MIP-2.	GYY 4137	10-17	C-X-C motif chemokine ligand 2	Homo sapiens	165-170
30441775-0	2018	The H2S Donor GYY4137 Stimulates Reactive Oxygen Species Generation in BV2 Cells While Suppressing the Secretion of TNF and Nitric Oxide.	GYY 4137	14-21	tumor necrosis factor	Mus musculus	116-119
30441775-4	2018	In this study, BV2 microglial cells were stimulated with interferon-gamma and lipopolysaccharide and treated with GYY4137.	GYY 4137	114-121	interferon gamma	Mus musculus	57-73
30341744-7	2018	CSE-/- animals received a 50 mug/g GYY4137-bolus after TxT.	GYY 4137	35-42	cystathionase (cystathionine gamma-lyase)	Mus musculus	0-3
30341744-11	2018	RESULTS: CSE-/- was associated with hypertension and lower blood glucose levels, partially and significantly restored by GYY4137 treatment, respectively.	GYY 4137	121-128	cystathionase (cystathionine gamma-lyase)	Mus musculus	9-12
29486221-9	2018	The level of S-sulfhydrated ATP5A1 was decreased in the adrenal gland of endotoxemic and CBS+/- mice, which was restored by GYY4137.	GYY 4137	124-131	ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1	Mus musculus	28-34
29486221-9	2018	The level of S-sulfhydrated ATP5A1 was decreased in the adrenal gland of endotoxemic and CBS+/- mice, which was restored by GYY4137.	GYY 4137	124-131	cystathionine beta-synthase	Mus musculus	89-92
29486221-11	2018	Overexpression of the cysteine 244 mutant ATP5A1 in Y1 cells resulted in a loss of LPS-induced mitochondria-mediated apoptosis and GYY4137 restoration of LPS-induced hyporesponsiveness to ACTH.	GYY 4137	131-138	ATP synthase F1 subunit alpha	Rattus norvegicus	42-48
30294900-9	2018	While GYY4137 suppressed ghrelin secretion, inhibition of CSE caused a stimulation in ghrelin secretion in primary gastric culture.	GYY 4137	6-13	ghrelin	Mus musculus	25-32
30294900-10	2018	In mice, GYY4137 treatment prolonged the postprandial drop of circulating ghrelin and caused reduced food consumption up to 4 h after treatment.	GYY 4137	9-16	ghrelin	Mus musculus	74-81
30294900-7	2018	We first demonstrated that GYY4137 (an H2 S donor molecule) directly suppresses ghrelin secretion in rat primary gastric culture, in part through the activation of the protein kinase B (AKT) pathway.	GYY 4137	27-34	ghrelin	Mus musculus	80-87
29522906-9	2018	RESULTS: GYY4137 led to a moderate decrease in post-obstructive serum creatinine, cystatin C and FENa.	GYY 4137	9-16	cystatin C	Rattus norvegicus	82-92
30294900-7	2018	We first demonstrated that GYY4137 (an H2 S donor molecule) directly suppresses ghrelin secretion in rat primary gastric culture, in part through the activation of the protein kinase B (AKT) pathway.	GYY 4137	27-34	AKT serine/threonine kinase 1	Rattus norvegicus	186-189
29622397-14	2018	Additionally, IP GYY4137 allowed for significant attenuation of inflammatory chemokine production of IL-6, IP-10 and MIP-2.	GYY 4137	17-24	interleukin 6	Homo sapiens	101-105
29622397-14	2018	Additionally, IP GYY4137 allowed for significant attenuation of inflammatory chemokine production of IL-6, IP-10 and MIP-2.	GYY 4137	17-24	C-X-C motif chemokine ligand 10	Homo sapiens	107-112
29622397-14	2018	Additionally, IP GYY4137 allowed for significant attenuation of inflammatory chemokine production of IL-6, IP-10 and MIP-2.	GYY 4137	17-24	C-X-C motif chemokine ligand 2	Homo sapiens	117-122
30186182-6	2018	We demonstrated that GYY4137-derived H2S increased food intake of mice, augmented the production of neuropeptide Y (NPY), and elevated the protein sulfur-sulfhydrylation level and the activation of AMPK and CaMKKbeta in ARC.	GYY 4137	21-28	neuropeptide Y	Mus musculus	100-114
30186182-6	2018	We demonstrated that GYY4137-derived H2S increased food intake of mice, augmented the production of neuropeptide Y (NPY), and elevated the protein sulfur-sulfhydrylation level and the activation of AMPK and CaMKKbeta in ARC.	GYY 4137	21-28	neuropeptide Y	Mus musculus	116-119
29383805-8	2018	Finally, we confirmed that GYY4137 inhibited iNOS expression via the NF-kappaB signaling pathway.	GYY 4137	27-34	nitric oxide synthase 2, inducible	Mus musculus	45-49
29730290-10	2018	Application of the H2S donor GYY4137 increased the number of RANKL-induced osteoclasts, the number of osteoclasts in periodontal tissues and tooth movement distance in CSE-/- mice.	GYY 4137	29-36	TNF superfamily member 11	Homo sapiens	61-66
29730290-10	2018	Application of the H2S donor GYY4137 increased the number of RANKL-induced osteoclasts, the number of osteoclasts in periodontal tissues and tooth movement distance in CSE-/- mice.	GYY 4137	29-36	cystathionase (cystathionine gamma-lyase)	Mus musculus	168-171
29522906-12	2018	Furthermore, our in vitro studies demonstrate that in the presence of TGF-beta1, GYY4137 significantly decreases vimentin and TbetaRII and significantly increases E-cadherin and Smad7.	GYY 4137	81-88	transforming growth factor, beta 1	Rattus norvegicus	70-79
29522906-12	2018	Furthermore, our in vitro studies demonstrate that in the presence of TGF-beta1, GYY4137 significantly decreases vimentin and TbetaRII and significantly increases E-cadherin and Smad7.	GYY 4137	81-88	vimentin	Rattus norvegicus	113-121
29522906-12	2018	Furthermore, our in vitro studies demonstrate that in the presence of TGF-beta1, GYY4137 significantly decreases vimentin and TbetaRII and significantly increases E-cadherin and Smad7.	GYY 4137	81-88	transforming growth factor, beta receptor 2	Rattus norvegicus	126-134
29522906-12	2018	Furthermore, our in vitro studies demonstrate that in the presence of TGF-beta1, GYY4137 significantly decreases vimentin and TbetaRII and significantly increases E-cadherin and Smad7.	GYY 4137	81-88	cadherin 1	Rattus norvegicus	163-173
29522906-12	2018	Furthermore, our in vitro studies demonstrate that in the presence of TGF-beta1, GYY4137 significantly decreases vimentin and TbetaRII and significantly increases E-cadherin and Smad7.	GYY 4137	81-88	SMAD family member 7	Rattus norvegicus	178-183
29605032-12	2018	CONCLUSIONS: GYY4137 activates the PHLPP-1/Akt/Nrf2 pathway to protect against diabetic myocardial ischemia/reperfusion injury.	GYY 4137	13-20	PH domain and leucine rich repeat protein phosphatase 1	Mus musculus	35-42
29605032-12	2018	CONCLUSIONS: GYY4137 activates the PHLPP-1/Akt/Nrf2 pathway to protect against diabetic myocardial ischemia/reperfusion injury.	GYY 4137	13-20	thymoma viral proto-oncogene 1	Mus musculus	43-46
29605032-0	2018	GYY4137 protects against myocardial ischemia/reperfusion injury via activation of the PHLPP-1/Akt/Nrf2 signaling pathway in diabetic mice.	GYY 4137	0-7	PH domain and leucine rich repeat protein phosphatase 1	Mus musculus	86-93
29605032-12	2018	CONCLUSIONS: GYY4137 activates the PHLPP-1/Akt/Nrf2 pathway to protect against diabetic myocardial ischemia/reperfusion injury.	GYY 4137	13-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	47-51
29605032-0	2018	GYY4137 protects against myocardial ischemia/reperfusion injury via activation of the PHLPP-1/Akt/Nrf2 signaling pathway in diabetic mice.	GYY 4137	0-7	thymoma viral proto-oncogene 1	Mus musculus	94-97
29163149-0	2017	GYY4137, an H2S Slow-Releasing Donor, Prevents Nitrative Stress and alpha-Synuclein Nitration in an MPTP Mouse Model of Parkinson"s Disease.	GYY 4137	0-7	synuclein alpha	Homo sapiens	68-83
29605032-0	2018	GYY4137 protects against myocardial ischemia/reperfusion injury via activation of the PHLPP-1/Akt/Nrf2 signaling pathway in diabetic mice.	GYY 4137	0-7	nuclear factor, erythroid derived 2, like 2	Mus musculus	98-102
29353375-4	2018	A dual inhibitor of the biosynthetic enzymes for H2S, cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CSE), amino-oxyacetic acid (AOA; 3 mM) reversed the inhibitory responses caused by GYY 4137, L-cysteine and N-acetylcysteine on K+-evoked [3H]D-aspartate release.	GYY 4137	202-210	cystathionine beta-synthase	Bos taurus	54-81
29353375-4	2018	A dual inhibitor of the biosynthetic enzymes for H2S, cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CSE), amino-oxyacetic acid (AOA; 3 mM) reversed the inhibitory responses caused by GYY 4137, L-cysteine and N-acetylcysteine on K+-evoked [3H]D-aspartate release.	GYY 4137	202-210	cystathionine gamma-lyase	Bos taurus	92-117
29187695-4	2018	Administration of GYY4137 (a slow-releasing H2S donor) significantly attenuated the severity of liver injury and was reflected by reduced inflammatory cytokine production and cell apoptosis, the levels of which were elevated by I/R, while DL-propargylglycine (PAG, an inhibitor of cystathionine gamma-lyase [CSE]) aggravated liver injury.	GYY 4137	18-25	cystathionine gamma-lyase	Homo sapiens	281-306
29163155-10	2017	We demonstrated the utility of coupling GYY4137 with either simvastatin, known to inhibit monocarboxylate transporter 4 (MCT4), or metformin, to further boost glycolysis, in bringing about cell death for aggressive cancers.	GYY 4137	40-47	solute carrier family 16 member 3	Homo sapiens	90-119
29163155-10	2017	We demonstrated the utility of coupling GYY4137 with either simvastatin, known to inhibit monocarboxylate transporter 4 (MCT4), or metformin, to further boost glycolysis, in bringing about cell death for aggressive cancers.	GYY 4137	40-47	solute carrier family 16 member 3	Homo sapiens	121-125
28645584-14	2017	IL-1beta increase in BAL fluid was abolished by both GYY4137 and NaHS treatments whereas TNF-alpha levels remained unchanged.	GYY 4137	53-60	interleukin 1 beta	Mus musculus	0-8
28977605-8	2017	We demonstrated that H2S donors (NaHS and GYY4137) directly stimulate GLP-1 secretion in murine L-cells (GLUTag) and that this occurs through p38 mitogen-activated protein kinase without affecting cell viability.	GYY 4137	42-49	glucagon	Mus musculus	70-75
28977605-8	2017	We demonstrated that H2S donors (NaHS and GYY4137) directly stimulate GLP-1 secretion in murine L-cells (GLUTag) and that this occurs through p38 mitogen-activated protein kinase without affecting cell viability.	GYY 4137	42-49	mitogen-activated protein kinase 14	Mus musculus	142-145
28484204-7	2017	In ex vivo experiments, Cardi-Braun  and del Nido cardioplegia solutions supplemented with GYY4137 significantly reduced the pro-apoptotic protein caspase-3 content and preserved ATP content.	GYY 4137	91-98	caspase 3	Homo sapiens	147-156
28404377-6	2017	SiRNA-mediated transient silencing of LDHA attenuated the GYY4137-induced stimulation of mitochondrial respiration, but not of glycolysis.	GYY 4137	58-65	lactate dehydrogenase A	Homo sapiens	38-42
28404377-9	2017	As shown in HCT116 cell whole extracts, in addition to LDHA activation, GYY4137 also stimulated LDHB activity, although to a smaller extent.	GYY 4137	72-79	lactate dehydrogenase B	Homo sapiens	96-100
28404377-12	2017	LDHA silencing sensitized HCT116 cells to glucose oxidase (GOx)-induced oxidative stress; this was further exacerbated with GYY4137 treatment.	GYY 4137	124-131	lactate dehydrogenase A	Homo sapiens	0-4
28404377-12	2017	LDHA silencing sensitized HCT116 cells to glucose oxidase (GOx)-induced oxidative stress; this was further exacerbated with GYY4137 treatment.	GYY 4137	124-131	hydroxyacid oxidase 1	Homo sapiens	42-57
28404377-12	2017	LDHA silencing sensitized HCT116 cells to glucose oxidase (GOx)-induced oxidative stress; this was further exacerbated with GYY4137 treatment.	GYY 4137	124-131	hydroxyacid oxidase 1	Homo sapiens	59-62
28404377-13	2017	Treatment with low concentrations of GYY4137 (0.3mM) or GOx (0.01U/ml) significantly increased the proliferation rate of HCT116 cells; the effect of GOx, but not the effect of GYY4137 was attenuated by LDHA silencing.	GYY 4137	37-44	hydroxyacid oxidase 1	Homo sapiens	149-152
28404377-13	2017	Treatment with low concentrations of GYY4137 (0.3mM) or GOx (0.01U/ml) significantly increased the proliferation rate of HCT116 cells; the effect of GOx, but not the effect of GYY4137 was attenuated by LDHA silencing.	GYY 4137	37-44	lactate dehydrogenase A	Homo sapiens	202-206
28615646-5	2017	The H2S-forming sulphur salt Na2S as well as the slow-releasing H2S-liberating compound GYY4137 increased transmembrane currents of CFTR-expressing oocytes.	GYY 4137	88-95	cystic fibrosis transmembrane conductance regulator L homeolog	Xenopus laevis	132-136
27819526-9	2017	Flow cytometry revealed an increase of CD62P/CD45 positive aggregates after TRAP stimulation of human whole blood, which was significantly reduced by preincubation with 30 mM GYY.	GYY 4137	175-178	selectin P	Homo sapiens	39-44
27819526-9	2017	Flow cytometry revealed an increase of CD62P/CD45 positive aggregates after TRAP stimulation of human whole blood, which was significantly reduced by preincubation with 30 mM GYY.	GYY 4137	175-178	protein tyrosine phosphatase receptor type C	Homo sapiens	45-49
27819526-9	2017	Flow cytometry revealed an increase of CD62P/CD45 positive aggregates after TRAP stimulation of human whole blood, which was significantly reduced by preincubation with 30 mM GYY.	GYY 4137	175-178	TRAP	Homo sapiens	76-80
28623294-5	2017	We found that homocysteine upregulates CSE but downregulates CBS whereas Na2S/GYY4137 downregulates CSE but upregulates CBS in a dose-dependent manner.	GYY 4137	78-85	cystathionase (cystathionine gamma-lyase)	Mus musculus	100-103
28623294-5	2017	We found that homocysteine upregulates CSE but downregulates CBS whereas Na2S/GYY4137 downregulates CSE but upregulates CBS in a dose-dependent manner.	GYY 4137	78-85	cystathionine beta-synthase	Mus musculus	120-123
28404873-8	2017	Moreover, PDE 5A homodimers were markedly decreased, and accordingly the PDE 5A activity demonstrated by the content of 5"-GMP was significantly decreased after incubation with NaHS or GYY4137.	GYY 4137	185-192	phosphodiesterase 5A	Rattus norvegicus	10-16
28404873-8	2017	Moreover, PDE 5A homodimers were markedly decreased, and accordingly the PDE 5A activity demonstrated by the content of 5"-GMP was significantly decreased after incubation with NaHS or GYY4137.	GYY 4137	185-192	phosphodiesterase 5A	Rattus norvegicus	73-79
28404873-9	2017	Mechanistically, both NaHS and GYY4137 significantly enhanced the PDE 5A sulfhydration in vascular tissues.	GYY 4137	31-38	phosphodiesterase 5A	Rattus norvegicus	66-72
27553476-4	2016	The results suggested that GYY4137 significantly attenuated LPS or TNF-alpha/IFN-gamma induced increased Caco-2 monolayer permeability.	GYY 4137	27-34	tumor necrosis factor	Mus musculus	67-76
28386344-0	2017	GYY4137 stimulates osteoblastic cell proliferation and differentiation via an ERK1/2-dependent anti-oxidant mechanism.	GYY 4137	0-7	mitogen-activated protein kinase 3	Mus musculus	78-84
28386344-4	2017	This research aims to explore the mechanism on how GYY4137 stimulates osteoblastic cell proliferation and differentiation via an ERK1/2-dependent anti-oxidant approach.	GYY 4137	51-58	mitogen-activated protein kinase 3	Mus musculus	129-135
28386344-13	2017	RT-PCR shows that GYY4137 stimulated the transcriptional levels of Runx2, a key transcription factor associated with osteoblast differentiation.	GYY 4137	18-25	runt related transcription factor 2	Mus musculus	67-72
28386344-17	2017	Western blotting analysis showed that the protective effects of GYY4137 were mediated by suppression of ERK1/2.	GYY 4137	64-71	mitogen-activated protein kinase 3	Mus musculus	104-110
28386344-18	2017	CONCLUSIONS: GYY4137 stimulates osteoblastic cell proliferation and bone differentiation via an ERK1/2-dependent anti-oxidant mechanism.	GYY 4137	13-20	mitogen-activated protein kinase 3	Mus musculus	96-102
26781077-8	2017	Preadministration of GYY4137 significantly attenuated acute lung injury induced by IAC, evidenced by reduced histologic scores and wet lung contents; improved blood gas parameters; reduced cell counts and protein amounts in bronchoalveolar lavage fluids; and reduced myeloperoxidase activity in lung tissues and plasma levels of tumor necrosis factor alpha, interleukin 6, and interleukin 1beta.	GYY 4137	21-28	interleukin 1 beta	Rattus norvegicus	377-394
26781077-11	2017	GYY4137 attenuated the increase of Ang2 release and expression and increased the phosphorylation of Akt and the activation of its downstream factors, glycogen synthase kinase 3beta and ribosomal protein S6 kinase; PAG showed opposite effects.	GYY 4137	0-7	angiopoietin 2	Rattus norvegicus	35-39
26781077-11	2017	GYY4137 attenuated the increase of Ang2 release and expression and increased the phosphorylation of Akt and the activation of its downstream factors, glycogen synthase kinase 3beta and ribosomal protein S6 kinase; PAG showed opposite effects.	GYY 4137	0-7	AKT serine/threonine kinase 1	Rattus norvegicus	100-103
26781077-11	2017	GYY4137 attenuated the increase of Ang2 release and expression and increased the phosphorylation of Akt and the activation of its downstream factors, glycogen synthase kinase 3beta and ribosomal protein S6 kinase; PAG showed opposite effects.	GYY 4137	0-7	glycogen synthase kinase 3 beta	Rattus norvegicus	150-180
26781077-11	2017	GYY4137 attenuated the increase of Ang2 release and expression and increased the phosphorylation of Akt and the activation of its downstream factors, glycogen synthase kinase 3beta and ribosomal protein S6 kinase; PAG showed opposite effects.	GYY 4137	0-7	ribosomal protein S6 kinase B1	Rattus norvegicus	185-212
27177428-12	2016	Epithelial-mesenchymal transition progression in LLC-PK1 was alleviated upon in vitro administration of GYY4137.	GYY 4137	104-111	prokineticin 1	Homo sapiens	53-56
28213404-12	2017	Taken together, our data suggest that downregulation of miR-129 plays a significant role in ANG II-induced renal inflammation and functional outcomes and that GYY4137 improves renal function by reversing miR-129 expression.NEW &amp; NOTEWORTHY We investigated epigenetic changes that occur in the hypertensive kidney and how H2S supplementation reverses adverse effects.	GYY 4137	159-166	microRNA 129	Mus musculus	204-211
26781077-8	2017	Preadministration of GYY4137 significantly attenuated acute lung injury induced by IAC, evidenced by reduced histologic scores and wet lung contents; improved blood gas parameters; reduced cell counts and protein amounts in bronchoalveolar lavage fluids; and reduced myeloperoxidase activity in lung tissues and plasma levels of tumor necrosis factor alpha, interleukin 6, and interleukin 1beta.	GYY 4137	21-28	myeloperoxidase	Rattus norvegicus	267-282
26781077-8	2017	Preadministration of GYY4137 significantly attenuated acute lung injury induced by IAC, evidenced by reduced histologic scores and wet lung contents; improved blood gas parameters; reduced cell counts and protein amounts in bronchoalveolar lavage fluids; and reduced myeloperoxidase activity in lung tissues and plasma levels of tumor necrosis factor alpha, interleukin 6, and interleukin 1beta.	GYY 4137	21-28	tumor necrosis factor	Rattus norvegicus	329-356
26781077-8	2017	Preadministration of GYY4137 significantly attenuated acute lung injury induced by IAC, evidenced by reduced histologic scores and wet lung contents; improved blood gas parameters; reduced cell counts and protein amounts in bronchoalveolar lavage fluids; and reduced myeloperoxidase activity in lung tissues and plasma levels of tumor necrosis factor alpha, interleukin 6, and interleukin 1beta.	GYY 4137	21-28	interleukin 6	Rattus norvegicus	358-371
27553476-4	2016	The results suggested that GYY4137 significantly attenuated LPS or TNF-alpha/IFN-gamma induced increased Caco-2 monolayer permeability.	GYY 4137	27-34	interferon gamma	Mus musculus	77-86
27553476-5	2016	The decreased expression of TJ (tight junction) proteins induced by LPS and the altered localization of TJs induced by TNF-alpha/IFN-gamma was significantly inhibited by GYY4137; similar results were obtained in vivo.	GYY 4137	170-177	tumor necrosis factor	Mus musculus	119-128
27553476-5	2016	The decreased expression of TJ (tight junction) proteins induced by LPS and the altered localization of TJs induced by TNF-alpha/IFN-gamma was significantly inhibited by GYY4137; similar results were obtained in vivo.	GYY 4137	170-177	interferon gamma	Mus musculus	129-138
27553476-7	2016	Increased level of TNF-alpha/IFN-gamma in the plasma and increased apoptosis in colon epithelial cells was also attenuated by GYY4137 in mice with endotoxemia.	GYY 4137	126-133	tumor necrosis factor	Mus musculus	19-28
27553476-7	2016	Increased level of TNF-alpha/IFN-gamma in the plasma and increased apoptosis in colon epithelial cells was also attenuated by GYY4137 in mice with endotoxemia.	GYY 4137	126-133	interferon gamma	Mus musculus	29-38
27708362-10	2016	In vitro, inhibition of CSE in HMEC-1 reduced tube formation, cell viability/proliferation, and migration which was restored after culture in the presence of H2S donor GYY4137.	GYY 4137	168-175	cystathionine gamma-lyase	Homo sapiens	24-27
26047341-7	2015	H2S-releasing compound GYY4137 attenuated the increases of TNF-alpha and IL-1beta in the plasma of HHcy mice and Hcy-treated raw264.7 cells while CSE inhibitor PAG exacerbated it.	GYY 4137	23-30	tumor necrosis factor	Mus musculus	59-68
27378570-11	2016	These data are the first to demonstrate that GYY4137 protects the heart against lethal reperfusion injury through activation of PI3K/Akt signalling, with partial dependency on NO signalling and inhibition of GSK-3beta during early reperfusion.	GYY 4137	45-52	AKT serine/threonine kinase 1	Homo sapiens	133-136
27378570-11	2016	These data are the first to demonstrate that GYY4137 protects the heart against lethal reperfusion injury through activation of PI3K/Akt signalling, with partial dependency on NO signalling and inhibition of GSK-3beta during early reperfusion.	GYY 4137	45-52	glycogen synthase kinase 3 beta	Homo sapiens	208-217
27038748-10	2016	GYY4137 caused a rapid decrease in type 2 sarco/endoplasmic calcium ATPase (SERCA2) mRNA and protein, which results in lower calcium levels in the endoplasmic reticulum compared to the control, untreated group.	GYY 4137	0-7	ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	Mus musculus	76-82
27378570-9	2016	Co-administration of L-NAME and GYY4137 attenuated the cardioprotection afforded by GYY4137, associated with attenuated phosphorylation of eNOS.	GYY 4137	32-39	nitric oxide synthase 3	Homo sapiens	139-143
26671149-6	2015	Furthermore, GYY4137 inhibited the Orai3 channel, a key component of the SOCE machinery.	GYY 4137	13-20	ORAI calcium release-activated calcium modulator 3	Mus musculus	35-40
26047341-7	2015	H2S-releasing compound GYY4137 attenuated the increases of TNF-alpha and IL-1beta in the plasma of HHcy mice and Hcy-treated raw264.7 cells while CSE inhibitor PAG exacerbated it.	GYY 4137	23-30	interleukin 1 beta	Mus musculus	73-81
25822632-4	2015	Expression of genes associated with adipogenesis related genes including fatty acid binding protein 4 (FABP4/aP2), a key regulator of this process, was increased by GYY4137 (a slow-releasing H2S donor compound) and sodium hydrosulfide (NaHS, a classical H2S donor) but not by ZYJ1122 or time-expired NaHS.	GYY 4137	165-172	fatty acid binding protein 4	Homo sapiens	73-101
25744413-7	2015	Administration of the hydrogen sulfide (H2S) donor GYY4137 inhibited NO production and reversed LPS-induced adrenocortical hyporesponsiveness.	GYY 4137	51-58	toll-like receptor 4	Mus musculus	96-99
25795259-3	2015	The present study attempts to investigate the effect of the gaseous signalling molecule hydrogen sulphide (H2S) on HIF-1alpha in THP-1 macrophages using the slow H2S releasing donor GYY4137.	GYY 4137	182-189	hypoxia inducible factor 1 subunit alpha	Homo sapiens	115-125
26060444-6	2015	Both H2S concentration in plasma and cystathionine-gamma-lyase (CSE) activity in the myocardium were enhanced in the GYY4137 treated groups.	GYY 4137	117-124	cystathionine gamma-lyase	Rattus norvegicus	37-62
26060444-6	2015	Both H2S concentration in plasma and cystathionine-gamma-lyase (CSE) activity in the myocardium were enhanced in the GYY4137 treated groups.	GYY 4137	117-124	cystathionine gamma-lyase	Rattus norvegicus	64-67
26060444-7	2015	GYY4137 also decreased malondialdehyde and myeloperoxidase levels in serum, attenuated superoxide anion level and suppressed phosphorylation of mitogen activated protein kinases in the myocardium after I/R.	GYY 4137	0-7	myeloperoxidase	Rattus norvegicus	43-58
26060444-8	2015	Meanwhile, GYY4137 increased the expression of Bcl-2 but decreased the expression of Bax, caspase-3 activity and apoptosis in the myocardium.	GYY 4137	11-18	BCL2, apoptosis regulator	Rattus norvegicus	47-52
26060444-8	2015	Meanwhile, GYY4137 increased the expression of Bcl-2 but decreased the expression of Bax, caspase-3 activity and apoptosis in the myocardium.	GYY 4137	11-18	BCL2 associated X, apoptosis regulator	Rattus norvegicus	85-88
26060444-8	2015	Meanwhile, GYY4137 increased the expression of Bcl-2 but decreased the expression of Bax, caspase-3 activity and apoptosis in the myocardium.	GYY 4137	11-18	caspase 3	Rattus norvegicus	90-99
25740991-4	2015	Using the slow-releasing H2S donor GYY4137 and propargylglycin (PAG), an inhibitor of cystathionine-gamma-lyase (CSE), a key enzyme that produces intracellular H2S, we found that RSV infection led to a reduced ability to generate and maintain intracellular H2S levels in airway epithelial cells (AECs).	GYY 4137	35-42	cystathionine gamma-lyase	Homo sapiens	86-111
25740991-4	2015	Using the slow-releasing H2S donor GYY4137 and propargylglycin (PAG), an inhibitor of cystathionine-gamma-lyase (CSE), a key enzyme that produces intracellular H2S, we found that RSV infection led to a reduced ability to generate and maintain intracellular H2S levels in airway epithelial cells (AECs).	GYY 4137	35-42	cystathionine gamma-lyase	Homo sapiens	113-116
25740991-9	2015	GYY4137 inhibition of proinflammatory gene expression occurred by modulation of the activation of the key transcription factors nuclear factor kappaB (NF-kappaB) and interferon regulatory factor 3 (IRF-3) at a step subsequent to their nuclear translocation.	GYY 4137	0-7	nuclear factor kappa B subunit 1	Homo sapiens	143-149
25740991-9	2015	GYY4137 inhibition of proinflammatory gene expression occurred by modulation of the activation of the key transcription factors nuclear factor kappaB (NF-kappaB) and interferon regulatory factor 3 (IRF-3) at a step subsequent to their nuclear translocation.	GYY 4137	0-7	nuclear factor kappa B subunit 1	Homo sapiens	151-160
25740991-9	2015	GYY4137 inhibition of proinflammatory gene expression occurred by modulation of the activation of the key transcription factors nuclear factor kappaB (NF-kappaB) and interferon regulatory factor 3 (IRF-3) at a step subsequent to their nuclear translocation.	GYY 4137	0-7	interferon regulatory factor 3	Homo sapiens	166-196
25740991-9	2015	GYY4137 inhibition of proinflammatory gene expression occurred by modulation of the activation of the key transcription factors nuclear factor kappaB (NF-kappaB) and interferon regulatory factor 3 (IRF-3) at a step subsequent to their nuclear translocation.	GYY 4137	0-7	interferon regulatory factor 3	Homo sapiens	198-203
25822632-4	2015	Expression of genes associated with adipogenesis related genes including fatty acid binding protein 4 (FABP4/aP2), a key regulator of this process, was increased by GYY4137 (a slow-releasing H2S donor compound) and sodium hydrosulfide (NaHS, a classical H2S donor) but not by ZYJ1122 or time-expired NaHS.	GYY 4137	165-172	fatty acid binding protein 4	Homo sapiens	103-108
25822632-4	2015	Expression of genes associated with adipogenesis related genes including fatty acid binding protein 4 (FABP4/aP2), a key regulator of this process, was increased by GYY4137 (a slow-releasing H2S donor compound) and sodium hydrosulfide (NaHS, a classical H2S donor) but not by ZYJ1122 or time-expired NaHS.	GYY 4137	165-172	fatty acid binding protein 4	Homo sapiens	109-112
26088607-10	2015	NOX4 expression was increased by hyperglycemia and high glucose, but was reduced in cardiac fibroblasts treated by NaHS and GYY4137.	GYY 4137	124-131	NADPH oxidase 4	Rattus norvegicus	0-4
26088607-11	2015	ROS production, ERK1/2 phosphorylation and MMP-2 and 9 expression were decreased in rat neonatal cardiac fibroblasts treated with GYY4137 and NOX4 siRNA.	GYY 4137	130-137	mitogen activated protein kinase 3	Rattus norvegicus	16-22
26088607-11	2015	ROS production, ERK1/2 phosphorylation and MMP-2 and 9 expression were decreased in rat neonatal cardiac fibroblasts treated with GYY4137 and NOX4 siRNA.	GYY 4137	130-137	matrix metallopeptidase 2	Rattus norvegicus	43-48
24114174-5	2014	We observed increased levels of the NCX1 mRNA, protein, and activity after 24 h of GYY4137 treatment.	GYY 4137	83-90	solute carrier family 8 member A1	Homo sapiens	36-40
24702258-9	2014	Local suppression of CBS or CSE in adrenal glands significantly increased the mortality in endotoxemic mice, which was also improved by GYY4137.	GYY 4137	136-143	cystathionine beta-synthase	Mus musculus	21-24
24702258-9	2014	Local suppression of CBS or CSE in adrenal glands significantly increased the mortality in endotoxemic mice, which was also improved by GYY4137.	GYY 4137	136-143	cystathionase (cystathionine gamma-lyase)	Mus musculus	28-31
24831018-13	2014	CONCLUSION: NaSH and GYY4137 show anti-inflammatory and anti-catabolic properties when added to IL1beta activated osteoarthritic CHs.	GYY 4137	21-28	interleukin 1 beta	Homo sapiens	96-103
26078813-6	2015	GYY4137 also inhibited angiotensin II- (Ang II-) induced neonatal rat cardiac fibroblast proliferation, reduced the number of fibroblasts in S phase, decreased collagen I and III mRNA expression and protein synthesis, attenuated oxidative stress, and suppressed alpha-smooth muscle actin (alpha-SMA), transforming growth factor-beta1 (TGF-beta1) expression as well as Smad2 phosphorylation.	GYY 4137	0-7	angiotensinogen	Rattus norvegicus	23-37
26078813-6	2015	GYY4137 also inhibited angiotensin II- (Ang II-) induced neonatal rat cardiac fibroblast proliferation, reduced the number of fibroblasts in S phase, decreased collagen I and III mRNA expression and protein synthesis, attenuated oxidative stress, and suppressed alpha-smooth muscle actin (alpha-SMA), transforming growth factor-beta1 (TGF-beta1) expression as well as Smad2 phosphorylation.	GYY 4137	0-7	actin gamma 2, smooth muscle	Rattus norvegicus	262-287
26078813-6	2015	GYY4137 also inhibited angiotensin II- (Ang II-) induced neonatal rat cardiac fibroblast proliferation, reduced the number of fibroblasts in S phase, decreased collagen I and III mRNA expression and protein synthesis, attenuated oxidative stress, and suppressed alpha-smooth muscle actin (alpha-SMA), transforming growth factor-beta1 (TGF-beta1) expression as well as Smad2 phosphorylation.	GYY 4137	0-7	actin gamma 2, smooth muscle	Rattus norvegicus	289-298
26078813-6	2015	GYY4137 also inhibited angiotensin II- (Ang II-) induced neonatal rat cardiac fibroblast proliferation, reduced the number of fibroblasts in S phase, decreased collagen I and III mRNA expression and protein synthesis, attenuated oxidative stress, and suppressed alpha-smooth muscle actin (alpha-SMA), transforming growth factor-beta1 (TGF-beta1) expression as well as Smad2 phosphorylation.	GYY 4137	0-7	transforming growth factor, beta 1	Rattus norvegicus	301-333
26078813-6	2015	GYY4137 also inhibited angiotensin II- (Ang II-) induced neonatal rat cardiac fibroblast proliferation, reduced the number of fibroblasts in S phase, decreased collagen I and III mRNA expression and protein synthesis, attenuated oxidative stress, and suppressed alpha-smooth muscle actin (alpha-SMA), transforming growth factor-beta1 (TGF-beta1) expression as well as Smad2 phosphorylation.	GYY 4137	0-7	transforming growth factor, beta 1	Rattus norvegicus	335-344
26078813-6	2015	GYY4137 also inhibited angiotensin II- (Ang II-) induced neonatal rat cardiac fibroblast proliferation, reduced the number of fibroblasts in S phase, decreased collagen I and III mRNA expression and protein synthesis, attenuated oxidative stress, and suppressed alpha-smooth muscle actin (alpha-SMA), transforming growth factor-beta1 (TGF-beta1) expression as well as Smad2 phosphorylation.	GYY 4137	0-7	SMAD family member 2	Rattus norvegicus	368-373
26078813-7	2015	These results indicate that GYY4137 improves myocardial fibrosis perhaps by a mechanism involving inhibition of oxidative stress, blockade of the TGF-beta1/Smad2 signaling pathway, and decrease in alpha-SMA expression in cardiac fibroblasts.	GYY 4137	28-35	transforming growth factor beta 1	Homo sapiens	146-155
26078813-7	2015	These results indicate that GYY4137 improves myocardial fibrosis perhaps by a mechanism involving inhibition of oxidative stress, blockade of the TGF-beta1/Smad2 signaling pathway, and decrease in alpha-SMA expression in cardiac fibroblasts.	GYY 4137	28-35	SMAD family member 2	Homo sapiens	156-161
26078813-7	2015	These results indicate that GYY4137 improves myocardial fibrosis perhaps by a mechanism involving inhibition of oxidative stress, blockade of the TGF-beta1/Smad2 signaling pathway, and decrease in alpha-SMA expression in cardiac fibroblasts.	GYY 4137	28-35	actin gamma 2, smooth muscle	Rattus norvegicus	197-206
24114174-6	2014	This increase was accompanied by elevated cAMP due to the GYY4137 treatment, which was completely abolished, when NCX1 was silenced.	GYY 4137	58-65	solute carrier family 8 member A1	Homo sapiens	114-118
24114174-8	2014	Indeed, GYY4137 increased expression of beta1 and beta3 (but not beta2) adrenergic receptors.	GYY 4137	8-15	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	40-55
24260346-3	2013	Also, cysl-2, a sulfhydrylase/cysteine synthase in C. elegans, was transcriptionally upregulated by GYY4137 treatment and the deletion of cysl-2 resulted in a significant reduction in lifespan which was partially recovered by the supplementation of GYY4137.	GYY 4137	100-107	Bifunctional L-3-cyanoalanine synthase/cysteine synthase	Caenorhabditis elegans	6-12
24535538-0	2014	GYY4137, a hydrogen sulfide (H2S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway.	GYY 4137	0-7	signal transducer and activator of transcription 3	Homo sapiens	114-119
24535538-2	2014	In this study, we discovered that GYY4137-mediated suppression of cell proliferation in human hepatocellular carcinoma (HCC) cell lines and tumor growth in a subcutaneous HepG2 xenograft model may be due to directly targeting the signal transducer and activator of transcription 3 (STAT3) pathway.	GYY 4137	34-41	signal transducer and activator of transcription 3	Homo sapiens	230-280
24535538-2	2014	In this study, we discovered that GYY4137-mediated suppression of cell proliferation in human hepatocellular carcinoma (HCC) cell lines and tumor growth in a subcutaneous HepG2 xenograft model may be due to directly targeting the signal transducer and activator of transcription 3 (STAT3) pathway.	GYY 4137	34-41	signal transducer and activator of transcription 3	Homo sapiens	282-287
24535538-3	2014	We found that GYY4137 suppressed STAT3 activation by reducing p-STAT3 (Y705) levels effectively in HepG2 and Bel7402 cells.	GYY 4137	14-21	signal transducer and activator of transcription 3	Homo sapiens	33-38
24535538-3	2014	We found that GYY4137 suppressed STAT3 activation by reducing p-STAT3 (Y705) levels effectively in HepG2 and Bel7402 cells.	GYY 4137	14-21	signal transducer and activator of transcription 3	Homo sapiens	64-69
24535538-6	2014	In vivo, GYY4137 significantly inhibited tumor growth in the subcutaneous HepG2 xenograft model by inhibiting STAT3 activation and its target gene expression.	GYY 4137	9-16	signal transducer and activator of transcription 3	Homo sapiens	110-115
24535538-7	2014	These results suggest that GYY4137-mediated suppression of HCC growth may be due to the inhibition of the STAT3 pathway.	GYY 4137	27-34	signal transducer and activator of transcription 3	Homo sapiens	106-111
24374752-0	2014	GYY4137, a novel hydrogen sulfide-releasing molecule, likely protects against high glucose-induced cytotoxicity by activation of the AMPK/mTOR signal pathway in H9c2 cells.	GYY 4137	0-7	mechanistic target of rapamycin kinase	Rattus norvegicus	138-142
24374752-3	2014	The present study was designed to determine whether GYY4137, a novel H2S-releasing molecule, protected H9c2 cells against high glucose (HG)-induced cytotoxicity by activation of the AMPK/mTOR signal pathway.	GYY 4137	52-59	mechanistic target of rapamycin kinase	Rattus norvegicus	187-191
24374752-11	2014	Importantly, both GYY4137 and AICAR increased AMPK phosphorylation and decreased mTOR phosphorylation compared with the HG model group while Ara-A attenuated GYY4137-mediated AMPK phosphorylation increase and mTOR phosphorylation decrement.	GYY 4137	18-25	mechanistic target of rapamycin kinase	Rattus norvegicus	81-85
24374752-11	2014	Importantly, both GYY4137 and AICAR increased AMPK phosphorylation and decreased mTOR phosphorylation compared with the HG model group while Ara-A attenuated GYY4137-mediated AMPK phosphorylation increase and mTOR phosphorylation decrement.	GYY 4137	18-25	mechanistic target of rapamycin kinase	Rattus norvegicus	209-213
24374752-11	2014	Importantly, both GYY4137 and AICAR increased AMPK phosphorylation and decreased mTOR phosphorylation compared with the HG model group while Ara-A attenuated GYY4137-mediated AMPK phosphorylation increase and mTOR phosphorylation decrement.	GYY 4137	158-165	mechanistic target of rapamycin kinase	Rattus norvegicus	81-85
24374752-11	2014	Importantly, both GYY4137 and AICAR increased AMPK phosphorylation and decreased mTOR phosphorylation compared with the HG model group while Ara-A attenuated GYY4137-mediated AMPK phosphorylation increase and mTOR phosphorylation decrement.	GYY 4137	158-165	mechanistic target of rapamycin kinase	Rattus norvegicus	209-213
24374752-12	2014	In conclusion, we propose that GYY4137 likely protects against HG-induced cytotoxicity by activation of the AMPK/mTOR signal pathway in H9c2 cells.	GYY 4137	31-38	mechanistic target of rapamycin kinase	Rattus norvegicus	113-117
23646934-6	2013	Polysulfide-mediated oxidation of PTEN was induced by all "H2S donors" tested, including sodium sulfide (Na2S), gaseous H2S, and morpholin-4-ium 4-methoxyphenyl(morpholino) phosphinodithioate (GYY4137).	GYY 4137	129-191	phosphatase and tensin homolog	Homo sapiens	34-38
23646934-6	2013	Polysulfide-mediated oxidation of PTEN was induced by all "H2S donors" tested, including sodium sulfide (Na2S), gaseous H2S, and morpholin-4-ium 4-methoxyphenyl(morpholino) phosphinodithioate (GYY4137).	GYY 4137	193-200	phosphatase and tensin homolog	Homo sapiens	34-38
24093496-7	2014	Treatment of C. elegans with GYY4137 increased the expression of several age-related, stress response, and antioxidant genes, whereas MitoSOX Red fluorescence, indicative of reactive oxygen species generation, was increased in mpst-1 knockouts and decreased by GYY4137 treatment.	GYY 4137	29-36	Putative thiosulfate sulfurtransferase mpst-1	Caenorhabditis elegans	227-233
24093496-8	2014	GYY4137 additionally increased the lifespan in short-lived mev-1 mutants with elevated oxidative stress and protected wild-type C. elegans against paraquat poisoning.	GYY 4137	0-7	Succinate dehydrogenase cytochrome b560 subunit, mitochondrial	Caenorhabditis elegans	59-64
24260346-3	2013	Also, cysl-2, a sulfhydrylase/cysteine synthase in C. elegans, was transcriptionally upregulated by GYY4137 treatment and the deletion of cysl-2 resulted in a significant reduction in lifespan which was partially recovered by the supplementation of GYY4137.	GYY 4137	100-107	Bifunctional L-3-cyanoalanine synthase/cysteine synthase	Caenorhabditis elegans	138-144
24260346-3	2013	Also, cysl-2, a sulfhydrylase/cysteine synthase in C. elegans, was transcriptionally upregulated by GYY4137 treatment and the deletion of cysl-2 resulted in a significant reduction in lifespan which was partially recovered by the supplementation of GYY4137.	GYY 4137	249-256	Bifunctional L-3-cyanoalanine synthase/cysteine synthase	Caenorhabditis elegans	6-12
24260346-3	2013	Also, cysl-2, a sulfhydrylase/cysteine synthase in C. elegans, was transcriptionally upregulated by GYY4137 treatment and the deletion of cysl-2 resulted in a significant reduction in lifespan which was partially recovered by the supplementation of GYY4137.	GYY 4137	249-256	Bifunctional L-3-cyanoalanine synthase/cysteine synthase	Caenorhabditis elegans	138-144
23582047-3	2013	RESULTS: In HeLa cell line, GYY4137 (10 mum) up-regulated expression of the IP3 R1 and IP3 R2, but not IP3 R3 on both mRNA and protein levels.	GYY 4137	28-35	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	76-82
24058499-10	2013	GYY4137 inhibited lipolysis in vivo without increasing fat mass, but also ameliorated the insulin resistance in HFD mice.	GYY 4137	0-7	insulin	Homo sapiens	90-97
24145109-9	2013	Both the inhibitors of cystathionine beta-synthase (aminooxyacetic acid, AOAA, 30 muM) and cystathionine gamma-lyase (propargylglycine, PAG, 1 mM) caused significant (p &lt; 0.05) rightward shifts in the concentration-response curve to GYY4137.	GYY 4137	236-243	cystathionine beta-synthase	Bos taurus	23-50
23582047-3	2013	RESULTS: In HeLa cell line, GYY4137 (10 mum) up-regulated expression of the IP3 R1 and IP3 R2, but not IP3 R3 on both mRNA and protein levels.	GYY 4137	28-35	inositol 1,4,5-trisphosphate receptor type 2	Homo sapiens	87-93
23582047-5	2013	Depletion of calcium from reticulum was accompanied by increase in endoplasmic reticulum (ER) stress markers, such as X-box, CHOP and ATF4, thus pointing to the development of ER stress due to GYY4137 treatment.	GYY 4137	193-200	DNA damage inducible transcript 3	Homo sapiens	125-129
23582047-5	2013	Depletion of calcium from reticulum was accompanied by increase in endoplasmic reticulum (ER) stress markers, such as X-box, CHOP and ATF4, thus pointing to the development of ER stress due to GYY4137 treatment.	GYY 4137	193-200	activating transcription factor 4	Homo sapiens	134-138
23356870-5	2013	Using recombinant human enzymes, GYY4137 inhibited the activity of COX-2, iNOS and TNF-alpha converting enzyme (TACE).	GYY 4137	33-40	prostaglandin-endoperoxide synthase 2	Homo sapiens	67-72
23713790-0	2013	The hydrogen sulfide donor, GYY4137, exhibits anti-atherosclerotic activity in high fat fed apolipoprotein E(-/-) mice.	GYY 4137	28-35	apolipoprotein E	Homo sapiens	92-108
23713790-5	2013	ApoE(-/-) mice were fed a high-fat diet for 4 weeks and administered GYY4137 for 30 days.	GYY 4137	69-76	apolipoprotein E	Mus musculus	0-4
23713790-11	2013	GYY4137 decreased the expression of lectin-like ox-LDL receptor-1, iNOS, phosphorylated IkappaBalpha, NF-kappaB, ICAM-1, VCAM-1 and chemokines, including CXCL2, CXCR4, CXCL10 and CCL17, but increased the scavenger protein CD36, in ox-LDL-treated RAW 264.7 cells.	GYY 4137	0-7	intercellular adhesion molecule 1	Mus musculus	113-119
23713790-12	2013	In vivo, GYY4137 decreased aortic atherosclerotic plaque formation and partially restored aortic endothelium-dependent relaxation in apoE(-/-) mice.	GYY 4137	9-16	apolipoprotein E	Mus musculus	133-137
23713790-13	2013	GYY4137 decreased ICAM-1, TNF-alpha and IL-6 mRNA expression as well as superoxide (O2 (-) ) generation in aorta.	GYY 4137	0-7	intercellular adhesion molecule 1	Mus musculus	18-24
23713790-13	2013	GYY4137 decreased ICAM-1, TNF-alpha and IL-6 mRNA expression as well as superoxide (O2 (-) ) generation in aorta.	GYY 4137	0-7	tumor necrosis factor	Mus musculus	26-35
23713790-13	2013	GYY4137 decreased ICAM-1, TNF-alpha and IL-6 mRNA expression as well as superoxide (O2 (-) ) generation in aorta.	GYY 4137	0-7	interleukin 6	Mus musculus	40-44
23713790-14	2013	In addition, GYY4137 increased aortic eNOS phosphorylation and expression of PI3K, enhanced Akt Ser(473) phosphorylation and down-regulated the expression of LOX-1.	GYY 4137	13-20	thymoma viral proto-oncogene 1	Mus musculus	92-95
23713790-14	2013	In addition, GYY4137 increased aortic eNOS phosphorylation and expression of PI3K, enhanced Akt Ser(473) phosphorylation and down-regulated the expression of LOX-1.	GYY 4137	13-20	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	158-163
23713790-16	2013	In vivo, GYY4137 decreased vascular inflammation and oxidative stress, improved endothelial function and reduced atherosclerotic plaque formation in apoE(-/-) mice.	GYY 4137	9-16	apolipoprotein E	Mus musculus	149-153
23454157-3	2013	RESULTS: On phenylephrine contracted preparations electrical field stimulation and the H2S donor GYY4137 evoked frequency and concentration dependent relaxation, which was reduced by desensitizing capsaicin sensitive primary afferents with capsaicin, and the blockade of adenosine 5"-triphosphate dependent K(+) channels, cyclooxygenase and cyclooxygenase-1 with glibenclamide, indomethacin and SC560, respectively.	GYY 4137	97-104	prostaglandin-endoperoxide synthase 1	Homo sapiens	341-357
23063804-8	2013	The H2S donor GYY4137 (0.1 nM to 10 muM) induced potent, concentration dependent relaxation, which was not modified by neuronal voltage gated Na(+) channels, or cystathionine gamma-lyase or cystathionine beta-synthase blockade.	GYY 4137	14-21	latexin	Homo sapiens	36-39
23063804-8	2013	The H2S donor GYY4137 (0.1 nM to 10 muM) induced potent, concentration dependent relaxation, which was not modified by neuronal voltage gated Na(+) channels, or cystathionine gamma-lyase or cystathionine beta-synthase blockade.	GYY 4137	14-21	cystathionine beta-synthase	Homo sapiens	190-217
23356870-4	2013	GYY4137 (0.1-0.5 mM) decreased LPS-induced production of nitrite (NO2 (-) ), PGE2 , TNF-alpha and IL-6 from HFLS and HAC, reduced the levels and catalytic activity of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and reduced LPS-induced NF-kappaB activation in vitro.	GYY 4137	0-7	tumor necrosis factor	Homo sapiens	84-93
23356870-4	2013	GYY4137 (0.1-0.5 mM) decreased LPS-induced production of nitrite (NO2 (-) ), PGE2 , TNF-alpha and IL-6 from HFLS and HAC, reduced the levels and catalytic activity of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and reduced LPS-induced NF-kappaB activation in vitro.	GYY 4137	0-7	interleukin 6	Homo sapiens	98-102
23356870-4	2013	GYY4137 (0.1-0.5 mM) decreased LPS-induced production of nitrite (NO2 (-) ), PGE2 , TNF-alpha and IL-6 from HFLS and HAC, reduced the levels and catalytic activity of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and reduced LPS-induced NF-kappaB activation in vitro.	GYY 4137	0-7	nitric oxide synthase 2	Homo sapiens	167-198
23356870-4	2013	GYY4137 (0.1-0.5 mM) decreased LPS-induced production of nitrite (NO2 (-) ), PGE2 , TNF-alpha and IL-6 from HFLS and HAC, reduced the levels and catalytic activity of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and reduced LPS-induced NF-kappaB activation in vitro.	GYY 4137	0-7	nitric oxide synthase 2	Homo sapiens	200-204
23356870-4	2013	GYY4137 (0.1-0.5 mM) decreased LPS-induced production of nitrite (NO2 (-) ), PGE2 , TNF-alpha and IL-6 from HFLS and HAC, reduced the levels and catalytic activity of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and reduced LPS-induced NF-kappaB activation in vitro.	GYY 4137	0-7	prostaglandin-endoperoxide synthase 2	Homo sapiens	210-226
23704251-8	2013	Finally, a slow-releasing H2S-generating compound, GYY4137, inhibited circulating soluble fms-like tyrosine kinase-1 and soluble endoglin levels and restored fetal growth in mice that was compromised by DL-propargylglycine treatment, demonstrating that the effect of CSE inhibitor was attributable to inhibition of H2S production.	GYY 4137	51-58	endoglin	Mus musculus	129-137
23704251-8	2013	Finally, a slow-releasing H2S-generating compound, GYY4137, inhibited circulating soluble fms-like tyrosine kinase-1 and soluble endoglin levels and restored fetal growth in mice that was compromised by DL-propargylglycine treatment, demonstrating that the effect of CSE inhibitor was attributable to inhibition of H2S production.	GYY 4137	51-58	cystathionase (cystathionine gamma-lyase)	Mus musculus	267-270
23356870-4	2013	GYY4137 (0.1-0.5 mM) decreased LPS-induced production of nitrite (NO2 (-) ), PGE2 , TNF-alpha and IL-6 from HFLS and HAC, reduced the levels and catalytic activity of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and reduced LPS-induced NF-kappaB activation in vitro.	GYY 4137	0-7	prostaglandin-endoperoxide synthase 2	Homo sapiens	228-233
23356870-5	2013	Using recombinant human enzymes, GYY4137 inhibited the activity of COX-2, iNOS and TNF-alpha converting enzyme (TACE).	GYY 4137	33-40	nitric oxide synthase 2	Homo sapiens	74-78
23356870-5	2013	Using recombinant human enzymes, GYY4137 inhibited the activity of COX-2, iNOS and TNF-alpha converting enzyme (TACE).	GYY 4137	33-40	ADAM metallopeptidase domain 17	Homo sapiens	83-110
23356870-5	2013	Using recombinant human enzymes, GYY4137 inhibited the activity of COX-2, iNOS and TNF-alpha converting enzyme (TACE).	GYY 4137	33-40	ADAM metallopeptidase domain 17	Homo sapiens	112-116
22842066-3	2012	We found that exogenous application of H(2)S (NaHS and GYY4137 as H(2)S donors) significantly enhances NO through increase of iNOS, in a manner Akt-dependent.	GYY 4137	55-62	inositol-3-phosphate synthase 1	Homo sapiens	126-130
22842066-3	2012	We found that exogenous application of H(2)S (NaHS and GYY4137 as H(2)S donors) significantly enhances NO through increase of iNOS, in a manner Akt-dependent.	GYY 4137	55-62	AKT serine/threonine kinase 1	Homo sapiens	144-147
21701688-7	2011	Mechanistic studies revealed that GYY4137 (400 microM) incubated for 5 days with MCF-7 but not IMR90 cells caused the generation of cleaved PARP and cleaved caspase 9, indicative of a pro-apoptotic effect.	GYY 4137	34-41	poly(ADP-ribose) polymerase 1	Homo sapiens	140-144
21701688-7	2011	Mechanistic studies revealed that GYY4137 (400 microM) incubated for 5 days with MCF-7 but not IMR90 cells caused the generation of cleaved PARP and cleaved caspase 9, indicative of a pro-apoptotic effect.	GYY 4137	34-41	caspase 9	Homo sapiens	157-166
19769459-4	2010	For the first time, we show that GYY4137 significantly and concentration-dependently inhibits LPS-induced release of proinflammatory mediators such as IL-1beta, IL-6, TNF-alpha, nitric oxide (*NO), and PGE(2) but increased the synthesis of the antiinflammatory chemokine IL-10 through NF-kappaB/ATF-2/HSP-27-dependent pathways.	GYY 4137	33-40	interleukin 1 beta	Homo sapiens	151-159
19769459-4	2010	For the first time, we show that GYY4137 significantly and concentration-dependently inhibits LPS-induced release of proinflammatory mediators such as IL-1beta, IL-6, TNF-alpha, nitric oxide (*NO), and PGE(2) but increased the synthesis of the antiinflammatory chemokine IL-10 through NF-kappaB/ATF-2/HSP-27-dependent pathways.	GYY 4137	33-40	interleukin 6	Homo sapiens	161-165
19769459-4	2010	For the first time, we show that GYY4137 significantly and concentration-dependently inhibits LPS-induced release of proinflammatory mediators such as IL-1beta, IL-6, TNF-alpha, nitric oxide (*NO), and PGE(2) but increased the synthesis of the antiinflammatory chemokine IL-10 through NF-kappaB/ATF-2/HSP-27-dependent pathways.	GYY 4137	33-40	tumor necrosis factor	Homo sapiens	167-176
19769459-4	2010	For the first time, we show that GYY4137 significantly and concentration-dependently inhibits LPS-induced release of proinflammatory mediators such as IL-1beta, IL-6, TNF-alpha, nitric oxide (*NO), and PGE(2) but increased the synthesis of the antiinflammatory chemokine IL-10 through NF-kappaB/ATF-2/HSP-27-dependent pathways.	GYY 4137	33-40	interleukin 10	Homo sapiens	271-276
19769459-4	2010	For the first time, we show that GYY4137 significantly and concentration-dependently inhibits LPS-induced release of proinflammatory mediators such as IL-1beta, IL-6, TNF-alpha, nitric oxide (*NO), and PGE(2) but increased the synthesis of the antiinflammatory chemokine IL-10 through NF-kappaB/ATF-2/HSP-27-dependent pathways.	GYY 4137	33-40	nuclear factor kappa B subunit 1	Homo sapiens	285-294
19769459-4	2010	For the first time, we show that GYY4137 significantly and concentration-dependently inhibits LPS-induced release of proinflammatory mediators such as IL-1beta, IL-6, TNF-alpha, nitric oxide (*NO), and PGE(2) but increased the synthesis of the antiinflammatory chemokine IL-10 through NF-kappaB/ATF-2/HSP-27-dependent pathways.	GYY 4137	33-40	activating transcription factor 2	Homo sapiens	295-300
19769459-4	2010	For the first time, we show that GYY4137 significantly and concentration-dependently inhibits LPS-induced release of proinflammatory mediators such as IL-1beta, IL-6, TNF-alpha, nitric oxide (*NO), and PGE(2) but increased the synthesis of the antiinflammatory chemokine IL-10 through NF-kappaB/ATF-2/HSP-27-dependent pathways.	GYY 4137	33-40	heat shock protein family B (small) member 1	Homo sapiens	301-307
19375498-3	2009	GYY4137 inhibited LPS-induced TNF-alpha production in rat blood and reduced the LPS-evoked rise in NF-kappaB activation, inducible nitric oxide synthase/cyclooxygenase-2 expression, and generation of PGE(2) and nitrate/nitrite in RAW 264.7 macrophages.	GYY 4137	0-7	tumor necrosis factor	Rattus norvegicus	30-39
19375498-5	2009	GYY4137 administration also decreased the LPS-evoked increase in lung myeloperoxidase activity, increased plasma concentration of the anti-inflammatory cytokine IL-10, and decreased tissue damage as determined histologically and by measurement of plasma creatinine and alanine aminotransferase activity.	GYY 4137	0-7	interleukin 10	Rattus norvegicus	161-166
19375498-7	2009	GYY4137 also decreased the LPS-mediated upregulation of liver transcription factors (NF-kappaB and STAT-3).	GYY 4137	0-7	signal transducer and activator of transcription 3	Rattus norvegicus	99-105
19375498-3	2009	GYY4137 inhibited LPS-induced TNF-alpha production in rat blood and reduced the LPS-evoked rise in NF-kappaB activation, inducible nitric oxide synthase/cyclooxygenase-2 expression, and generation of PGE(2) and nitrate/nitrite in RAW 264.7 macrophages.	GYY 4137	0-7	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	153-169
19375498-4	2009	GYY4137 (50 mg/kg, ip) administered to conscious rats 1 or 2 h after (but not 1 h before) LPS decreased the subsequent (4 h) rise in plasma proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6), nitrite/nitrate, C-reactive protein, and L-selectin.	GYY 4137	0-7	tumor necrosis factor	Rattus norvegicus	167-176
19375498-4	2009	GYY4137 (50 mg/kg, ip) administered to conscious rats 1 or 2 h after (but not 1 h before) LPS decreased the subsequent (4 h) rise in plasma proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6), nitrite/nitrate, C-reactive protein, and L-selectin.	GYY 4137	0-7	interleukin 1 beta	Rattus norvegicus	178-186
19375498-4	2009	GYY4137 (50 mg/kg, ip) administered to conscious rats 1 or 2 h after (but not 1 h before) LPS decreased the subsequent (4 h) rise in plasma proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6), nitrite/nitrate, C-reactive protein, and L-selectin.	GYY 4137	0-7	interleukin 6	Rattus norvegicus	188-192
19375498-4	2009	GYY4137 (50 mg/kg, ip) administered to conscious rats 1 or 2 h after (but not 1 h before) LPS decreased the subsequent (4 h) rise in plasma proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6), nitrite/nitrate, C-reactive protein, and L-selectin.	GYY 4137	0-7	C-reactive protein	Rattus norvegicus	212-230
19375498-4	2009	GYY4137 (50 mg/kg, ip) administered to conscious rats 1 or 2 h after (but not 1 h before) LPS decreased the subsequent (4 h) rise in plasma proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6), nitrite/nitrate, C-reactive protein, and L-selectin.	GYY 4137	0-7	selectin L	Rattus norvegicus	236-246